<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Deliv</journal-id><journal-id journal-id-type="iso-abbrev">Drug Deliv</journal-id><journal-title-group><journal-title>Drug Delivery</journal-title></journal-title-group><issn pub-type="ppub">1071-7544</issn><issn pub-type="epub">1521-0464</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7751395</article-id><article-id pub-id-type="pmid">33336610</article-id><article-id pub-id-type="doi">10.1080/10717544.2020.1856225</article-id><article-id pub-id-type="publisher-id">1856225</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials</article-title><alt-title alt-title-type="left-running-head">X. Cheng et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7143-0388</contrib-id><name><surname>Cheng</surname><given-names>Xi</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Jinrong</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Ge</surname><given-names>Qi</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Xing</surname><given-names>Danlei</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Xuefeng</given-names></name><xref ref-type="aff" rid="AF0002">b</xref><xref ref-type="corresp" rid="AN0003"/></contrib><contrib contrib-type="author"><name><surname>Qian</surname><given-names>Yunzhu</given-names></name><xref ref-type="aff" rid="AF0003">c</xref><xref ref-type="corresp" rid="AN0002"/></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Guoqin</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Surgery, The Second Affiliated Hospital of Soochow University</institution>, <city>Suzhou</city>, <country>People&#x02019;s Republic of China</country></aff><aff id="AF0002"><label>b</label><institution>State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University</institution>, <city>Nanjing</city>, <country>People&#x02019;s Republic of China</country></aff><aff id="AF0003"><label>c</label><institution>Center of Stomatology, The Second Affiliated Hospital of Soochow University</institution>, <city>Suzhou</city>, <country>People&#x02019;s Republic of China</country></aff></contrib-group><author-notes><corresp id="AN0001"><bold>CONTACT</bold> Guoqin Jiang <email>jiang_guoqin@suda.edu.cn</email><institution>Department of Surgery, The Second Affiliated Hospital of Soochow University</institution>, <addr-line>No 1055, San-Xiang Road</addr-line>, <city>Suzhou</city><postal-code>215004</postal-code>, <country>People&#x02019;s Republic of China</country></corresp><corresp id="AN0002">Yunzhu Qian <email>yunzhu_qian@sina.com</email><institution>Center of Stomatology, The Second Affiliated Hospital of Soochow University</institution>, <addr-line>No. 1055, Sanxiang Road</addr-line>, <city>Suzhou</city><postal-code>215004</postal-code>, <country>People&#x02019;s Republic of China</country></corresp><corresp id="AN0003">Xuefeng Zhou <email>zhouxuefeng@seu.edu.cn</email><institution>State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University</institution>, <addr-line>No. 2 Sipailou, Xuanwu District</addr-line>, <city>Nanjing</city><postal-code>210096</postal-code>, <country>People&#x02019;s Republic of China</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>18</day><month>12</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2021</year></pub-date><volume>28</volume><issue>1</issue><fpage seq="4">37</fpage><lpage>53</lpage><permissions><copyright-statement>&#x000a9; 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IDRD_28_1856225.pdf"/><abstract><title>Abstract</title><p>Some cancers such as human breast cancer, prostate cancer, and lung cancer easily metastasize to bone, leading to osteolysis and bone destruction accompanied by a complicated microenvironment. Systemic administration of bisphosphonates (BP) or denosumab is the routine therapy for osteolysis but with non-negligible side effects such as mandibular osteonecrosis and hypocalcemia. Thus, it is imperative to exploit optimized drug delivery systems, and some novel nanotechnology and nanomaterials have opened new horizons for scientists. Targeted and local drug delivery systems can optimize biodistribution depending on nanoparticles (NPs) or microspheres (MS) and implantable biomaterials with the controllable property. Drug delivery kinetics can be optimized by smart and sustained/local drug delivery systems for responsive delivery and sustained delivery. These delicately fabricated drug delivery systems with special matrix, structure, morphology, and modification can minimize unexpected toxicity caused by systemic delivery and achieve desired effects through integrating multiple drugs or multiple functions. This review summarized recent studies about optimized drug delivery systems for the treatment of cancer metastatic osteolysis, aimed at giving some inspiration in designing efficient multifunctional drug delivery systems.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Osteolysis</kwd><kwd>cancer bone metastasis</kwd><kwd>drug delivery systems</kwd><kwd>nanomaterials</kwd></kwd-group><counts><fig-count count="7"/><table-count count="3"/><page-count count="17"/><word-count count="12661"/></counts></article-meta></front><body><sec id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>Bone metastasis and concomitant complications are huge challenges for cancer treatment in the clinic. Bone metastases occur in about 70% of patients suffering from advanced breast cancer or prostate cancer and approximately 15&#x02013;30% of patients with carcinoma of the lung, colon, stomach, bladder, uterus, rectum, thyroid, or kidney (Irelli et&#x000a0;al., <xref rid="CIT0053" ref-type="bibr">2016</xref>; Sun, Han, et&#x000a0;al., <xref rid="CIT0116" ref-type="bibr">2016</xref>). Escaping from the tumor <italic>in-situ</italic>, tumor cells enter circulation through blood vessels and lymph vessels and then travel all over the body to find fertile soil to proliferate (Croucher et&#x000a0;al., <xref rid="CIT0023" ref-type="bibr">2016</xref>; Vinay &#x00026; KusumDevi, <xref rid="CIT0125" ref-type="bibr">2016</xref>; Chen, Pei, et&#x000a0;al., <xref rid="CIT0017" ref-type="bibr">2018</xref>; Ahangar et&#x000a0;al., <xref rid="CIT0004" ref-type="bibr">2019</xref>). The special structure and microenvironment of the bone marrow are beneficial for tumor cells to grow (Ahangar et&#x000a0;al., <xref rid="CIT0004" ref-type="bibr">2019</xref>). Tumor cells replicate in the new environment continually, develop into a metastatic tumor, and destroy the bone structure. Patients with bone metastasis suffer from bone pain, pathological fracture, hypercalcemia, spinal cord compression, and other skeletal-related events (Macedo et&#x000a0;al., <xref rid="CIT0080" ref-type="bibr">2017</xref>; Turpin et&#x000a0;al., <xref rid="CIT0121" ref-type="bibr">2020</xref>). Osteogenic metastasis or osteolytic metastasis both could happen. But osteolytic bone metastases account for approximately 80% of cancer bone metastases (Sun, Ge, et&#x000a0;al., <xref rid="CIT0115" ref-type="bibr">2019</xref>). The &#x02018;vicious circle&#x02019; occurring in the metastasized bone accelerates the cancer cells&#x02019; proliferation and bone destruction at the same time (Santini et&#x000a0;al., <xref rid="CIT0101" ref-type="bibr">2010</xref>; Turpin et&#x000a0;al., <xref rid="CIT0121" ref-type="bibr">2020</xref>). BP and denosumab are common medicine in the clinic but have many side effects. BP may cause mandibular osteonecrosis and impair renal function (Sun, Han, et&#x000a0;al., <xref rid="CIT0116" ref-type="bibr">2016</xref>). Denosumab was reported to increase the risk of pancreatitis and endocarditis, erysipelas, and infectious arthritis (Jie et&#x000a0;al., <xref rid="CIT0055" ref-type="bibr">2019</xref>). Some newly developed drugs have not been used clinically due to their hydrophobicity, short half-life, and other disadvantages (Chew &#x00026; Danti, <xref rid="CIT0020" ref-type="bibr">2017</xref>). These undesired effects of systemic drug delivery arise from the uncontrollable &#x02018;space&#x02019; and &#x02018;time&#x02019; of drug reaction. Delightedly, nanotechnology and nanomaterials provide new strategies to build superior drug delivery systems that make drugs more efficient and secure to the body (Chen, Wang, et&#x000a0;al., <xref rid="CIT0018" ref-type="bibr">2019</xref>). Many kinds of NPs were utilized as drug carriers and targeted destroyed bone areas to treat cancer and inhibit bone resorption, such as polymer NPs, liposomes, and silica NPs. Elaborate decorations with targeting ligands endowed particles the ability to target bone or special expression of cancer cells in the osteolytic microenvironment, optimizing the spatial distribution of drugs. The multifunctional implantable scaffolds or hydrogel materials can load a large number of drugs and release drugs locally in a more sustainable way, showing desired efficiency and minimal side effects and reducing the frequency of medication. In addition, smart drug release systems were designed to release drugs in response to some physical and chemical stimuli. Internal chemical characteristics of the osteolytic environment (low pH and high Ca<sup>2+</sup> concentration) and external physical stimuli [near-infrared light (NIR), ultraviolet light, or ultrasound] both can be utilized as triggers of drug release and further optimize the timing of delivery. <xref ref-type="fig" rid="F0001">Figure 1</xref> summarized the work of these optimized drug delivery systems.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>The graphical abstract of the work of optimized drug delivery systems.</p></caption><graphic content-type="color" xlink:href="IDRD_A_1856225_F0001_C"/></fig></sec><sec id="S0002" disp-level="1"><label>2.</label><title>Osteolytic cancer bone metastasis</title><p>When metastatic tumor forms, tumor cells interact with normal cells in the vicinity, influence their cellular function, and destroy the primary microenvironment (Futakuchi et&#x000a0;al., <xref rid="CIT0038" ref-type="bibr">2016</xref>; Shupp et&#x000a0;al., <xref rid="CIT0107" ref-type="bibr">2018</xref>). Bone offers metastatic cells unique microenvironments termed &#x02018;niches&#x02019; (Croucher et&#x000a0;al., <xref rid="CIT0023" ref-type="bibr">2016</xref>; Ahangar et&#x000a0;al., <xref rid="CIT0004" ref-type="bibr">2019</xref>). The slow blood flow in bone, mechanical property, various chemokines, and growth factors are beneficial to tumor cells&#x02019; growth (Zhu et&#x000a0;al., <xref rid="CIT0153" ref-type="bibr">2018</xref>; Turpin et&#x000a0;al., <xref rid="CIT0121" ref-type="bibr">2020</xref>). In the osteolytic microenvironment, the &#x02018;vicious circle&#x02019; between cancer cells, osteoblasts, and osteoclasts facilitates the activation of osteoclasts and suppresses the action of osteoblasts. At the same time, cancer cells&#x02019; proliferation is also promoted continually (Futakuchi et&#x000a0;al., <xref rid="CIT0038" ref-type="bibr">2016</xref>; Saracino et&#x000a0;al., <xref rid="CIT0103" ref-type="bibr">2016</xref>; Turpin et&#x000a0;al., <xref rid="CIT0121" ref-type="bibr">2020</xref>). In brief, metastatic cancer cells produce and excrete parathyroid hormone-related protein (PTHrP), IL-11, TNF-a, and other factors that act on the osteoblasts to promote the expression of receptor activator of nuclear factor-&#x003ba;B (NF-&#x003ba;B) ligand (RANKL). RANKL combines with receptor activator of NF-&#x003ba;B (RANK) on the membrane of preosteoclasts to accelerate osteoclast formation and maturity (Wu et&#x000a0;al., <xref rid="CIT0138" ref-type="bibr">2020</xref>). Cancer cells also express the Notch ligand Jagged1 and VCAM-1 to promote the activation of preosteoclasts (Lu et&#x000a0;al., <xref rid="CIT0076" ref-type="bibr">2011</xref>; Sethi et&#x000a0;al., <xref rid="CIT0106" ref-type="bibr">2011</xref>). The bone matrix contains a variety of growth factors, such as insulin-like growth factors (IGFs), transforming growth factor &#x003b2; (TGF-&#x003b2;), fibroblast growth factors (FGFs), platelet-derived growth factors (PDGFs), and bone morphogenetic proteins (BMP) (Kagiya, <xref rid="CIT0056" ref-type="bibr">2015</xref>; Vinay &#x00026; KusumDevi, <xref rid="CIT0125" ref-type="bibr">2016</xref>). These growth factors are released from the bone matrix during the bone resorption caused by mature osteoclasts. TGF-&#x003b2; acts on cancer cells to facilitate its proliferation and production of more PTHrP. Osteoprotegerin (OPG), also produced by osteoblasts, is a soluble RANKL decoy receptor that can prevent osteoclasts formation and osteoclastic bone resorption (Wu et&#x000a0;al., <xref rid="CIT0138" ref-type="bibr">2020</xref>). However, the production of OPG is suppressed by matric meralloproteinases (MMPs) during this &#x02018;vicious circle&#x02019; (Lu et&#x000a0;al., <xref rid="CIT0077" ref-type="bibr">2009</xref>). Additionally, cancer cells secrete a macrophage-stimulating protein (MSP) to promote osteoclasts activation directly via the receptor on the osteoclasts, RON tyrosine kinase (Andrade et&#x000a0;al., <xref rid="CIT0007" ref-type="bibr">2017</xref>). The diagram description of the interaction between cells in the osteolytic microenvironment is shown in <xref ref-type="fig" rid="F0002">Figure 2</xref>. Also, many microRNAs are involved in osteolysis, such as miR-21, miR-133a, miR-33a, miR-190, and miR-223 (Probert et&#x000a0;al., <xref rid="CIT0093" ref-type="bibr">2019</xref>).</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>&#x02018;Vicious circle&#x02019; in osteolysis caused by cancer bone metastasis.</p></caption><graphic content-type="color" xlink:href="IDRD_A_1856225_F0002_C"/></fig><p>Nowadays, radiotherapy, surgery as well as systemic drug therapies (chemotherapy, hormone therapy), and targeted therapy are effective clinical therapies for osteolysis. The efficacy of BP appeared to be time-dependent and they were effective after 6&#x02013;12&#x02009;months of therapy (Irelli et&#x000a0;al., <xref rid="CIT0053" ref-type="bibr">2016</xref>). Denosumab is a kind of human monoclonal antibody that combines especially with RANKL to inhibit the activation of osteoclasts. Many experiments showed that Denosumab was more effective than zoledronic acid (Zol or ZA) and caused fewer side effects (Stopeck et&#x000a0;al., <xref rid="CIT0111" ref-type="bibr">2010</xref>; Irelli et&#x000a0;al., <xref rid="CIT0053" ref-type="bibr">2016</xref>; Chen, He, et&#x000a0;al., <xref rid="CIT0014" ref-type="bibr">2019</xref>; Turpin et&#x000a0;al., <xref rid="CIT0121" ref-type="bibr">2020</xref>). However, Denosumab cannot accumulate in the bone like BP and its effect is reversible after treatment discontinuation (Macedo et&#x000a0;al., <xref rid="CIT0080" ref-type="bibr">2017</xref>).</p></sec><sec id="S0003" disp-level="1"><label>3.</label><title>Therapeutic agents</title><sec id="S0003-S2001" disp-level="2"><label>3.1.</label><title>Chemotherapeutic drugs</title><p>The theme of treating osteolysis is killing cancer cells and suppressing osteoclasts synchronously. So the optimized drug delivery systems usually loaded one kind of anticancer drugs like paclitaxel (PTX), doxorubicin (DOX), platinum (Pt), and one kind of anti-osteoclasts drugs simultaneously. Here, we emphatically introduced potent drugs and novel drugs for suppressing osteoclasts.</p><p>BP is a stable analog of pyrophosphate by replacing the P&#x02013;O&#x02013;P bonds with P&#x02013;C&#x02013;P bonds (Rudnick-Glick et&#x000a0;al., <xref rid="CIT0099" ref-type="bibr">2016</xref>). This makes BP enzymatically stable. BP has a high affinity to the bone mineral hydroxyapatite (HA) and has been exploited as a targeting ligand. Osteoclasts can take up and be suppressed by BP chelating to bone (Zeng et&#x000a0;al., <xref rid="CIT0145" ref-type="bibr">2019</xref>). In addition, BP has been revealed to be able to inhibit cancer cells (Robert &#x00026; Reinhold, <xref rid="CIT0097" ref-type="bibr">2015</xref>; Santini et&#x000a0;al., <xref rid="CIT0102" ref-type="bibr">2015</xref>). Hydroxyapatite nanoparticles (nHA) was always applied in bone repairing because of its good biocompatibility to the bone and fine adsorption to BP. Recently, nHA has been found to be able to inhibit several kinds of cancer cells through mitochondrial-dependent apoptosis and have special functions of lessening osteolysis caused by cancer metastasis (Zhang, Zhou, et&#x000a0;al., <xref rid="CIT0148" ref-type="bibr">2019</xref>). The transcription factor Gli2 is a key regulator of PTHrP (Vanderburgh et&#x000a0;al., <xref rid="CIT0124" ref-type="bibr">2019</xref>). And GANT58 is a Gli2 antagonist that inhibits Gli2 nuclear translocation and PTHrP expression in tumor cells to play a role in hindering the &#x02018;vicious circle&#x02019; (Vanderburgh et&#x000a0;al., <xref rid="CIT0124" ref-type="bibr">2019</xref>). Gallium (Ga) is a semi-metallic element with a chemical affinity for biological HA, anti-resorption activity and anticancer ability. Ga significantly decreased osteoclasts differentiation and activity without negative interaction with osteoblasts (Strazic-Geljic et&#x000a0;al., <xref rid="CIT0112" ref-type="bibr">2016</xref>). Odanacatib and balicatib, inhibitors of cathepsin K, can suppress bone resorption (Saracino et&#x000a0;al., <xref rid="CIT0103" ref-type="bibr">2016</xref>). Mature osteoclasts express cathepsin K which is a kind of lysosomal cysteine protease essential for collagen and elastin degradation during bone resorption. <xref rid="t0001" ref-type="table">Table 1</xref> collected some reported effective drugs for suppressing osteoclasts and some other potential drugs (Vinay &#x00026; KusumDevi, <xref rid="CIT0125" ref-type="bibr">2016</xref>).</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>The drugs with contributions to block &#x02018;vicious circle.&#x02019;</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Drugs</th><th align="center">Mechanism</th><th align="center">Reference</th></tr></thead><tbody valign="top"><tr><td align="left">BP</td><td align="left">Non-nitrogen containing: inhibiting ATP hydrolysis<break/>Nitrogen containing: prevents protein prenylation of small GTPases</td><td align="left">(Vinay &#x00026; KusumDevi, <xref ref-type="bibr" rid="CIT0125">2016</xref>);<break/>(O&#x02019;Carrigan et&#x000a0;al., <xref ref-type="bibr" rid="CIT0086">2017</xref>); <break/>(Horne et&#x000a0;al., <xref ref-type="bibr" rid="CIT0050">2018</xref>)</td></tr><tr><td align="left">Denosumab</td><td align="left">Antibody to RANKL</td><td align="left">(Gul et&#x000a0;al., <xref ref-type="bibr" rid="CIT0045">2016</xref>); <break/>(Lipton et&#x000a0;al., <xref ref-type="bibr" rid="CIT0070">2016</xref>); (Stopeck et&#x000a0;al., <xref ref-type="bibr" rid="CIT0110">2016</xref>)</td></tr><tr><td align="left">Odanacatib and balicatib and L-235</td><td align="left">Inhibit cathepskin K</td><td align="left">(Saracino et&#x000a0;al., <xref ref-type="bibr" rid="CIT0103">2016</xref>); <break/>(Duong et&#x000a0;al., <xref ref-type="bibr" rid="CIT0032">2014</xref>)</td></tr><tr><td align="left">BTZ</td><td align="left">Inhibit NF-kB pathway in osteoclast</td><td align="left">(Zhu et&#x000a0;al., <xref ref-type="bibr" rid="CIT0153">2018</xref>); <break/>(Wang, Cai, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0126">2018</xref>)</td></tr><tr><td align="left">GANT58</td><td align="left">Inhibits Gli2 nuclear translocation and PTHrP expression in tumor cells</td><td align="left">(Vanderburgh et&#x000a0;al., <xref ref-type="bibr" rid="CIT0124">2019</xref>);<break/>(Vanderburgh et&#x000a0;al., <xref ref-type="bibr" rid="CIT0123">2020</xref>)</td></tr><tr><td align="left">nHA</td><td align="left">Mitochondrial-dependent apoptosis</td><td align="left">(Zhang, Zhou, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0147">2019</xref>); <break/>(Sun, Chen, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0114">2016</xref>)</td></tr><tr><td align="left">BMS-777607/ASLAN002</td><td align="left">Inhibit MSP/RON signaling pathway</td><td align="left">(Andrade et&#x000a0;al., <xref ref-type="bibr" rid="CIT0007">2017</xref>)</td></tr><tr><td align="left">Ga</td><td align="left">Decrease RANKL-induced initial expression and auto-amplification of NFATc1</td><td align="left">(Strazic-Geljic et&#x000a0;al., <xref ref-type="bibr" rid="CIT0112">2016</xref>)</td></tr><tr><td align="left">Quetiapine</td><td align="left">Inhibiting RANKL-mediated MAPK and NF-&#x003ba;B signaling pathways</td><td align="left">(Wang et&#x000a0;al., <xref ref-type="bibr" rid="CIT0130">2015</xref>)</td></tr><tr><td align="left">PKI-402</td><td align="left">Impair the PI3K-AKT-mTOR signaling pathways</td><td align="left">(Yuan et&#x000a0;al., <xref ref-type="bibr" rid="CIT0144">2019</xref>)</td></tr><tr><td align="left">Dasatinib</td><td align="left">Inhibit Src activity</td><td align="left">(Irelli et&#x000a0;al., <xref ref-type="bibr" rid="CIT0053">2016</xref>)</td></tr><tr><td align="left">Chinese herbs extractions/plant extractions:</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">&#x02003;Licorice isoliquiritigenin (ISL)</td><td align="left">Anti RANKL-induced osteoclast generation</td><td align="left">(Sun, Zhang, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0117">2019</xref>)</td></tr><tr><td align="left">&#x02003;Curcumin</td><td align="left">Suppress gene <break/>products regulated by NF-&#x003ba;B</td><td align="left">(Wang, Guo, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0127">2018</xref>);<break/>(Yang et&#x000a0;al., <xref ref-type="bibr" rid="CIT0142">2020</xref>);<break/>(An et&#x000a0;al., <xref ref-type="bibr" rid="CIT0006">2018</xref>)</td></tr><tr><td align="left">&#x02003;Quercetin</td><td align="left">Anti-oxidant</td><td align="left">(Forte et&#x000a0;al., <xref ref-type="bibr" rid="CIT0037">2017</xref>);<break/>(Zhang et&#x000a0;al., <xref ref-type="bibr" rid="CIT0146">2017</xref>);<break/>(Ge et&#x000a0;al., <xref ref-type="bibr" rid="CIT0041">2020</xref>)</td></tr><tr><td align="left">&#x02003;Plumbagin (PL)</td><td align="left">Abrogated RANKL-induced NF-&#x003ba;B and MAPK pathways by blocking RANK association with TRAF6 in osteoclastogenesis</td><td align="left">(Qiao et&#x000a0;al., <xref ref-type="bibr" rid="CIT0094">2017</xref>); <break/>(Li et&#x000a0;al., <xref ref-type="bibr" rid="CIT0067">2012</xref>)</td></tr><tr><td align="left">&#x02003;Artemisinin, Dihydroartemisinin</td><td align="left">Reduced expression of genes involved in osteoclast formation, suppressed osteoclast differentiation, F-actin ring formation and bone resorption through suppressing AKT/SRC pathways</td><td align="left">(Ma et&#x000a0;al., <xref ref-type="bibr" rid="CIT0079">2018</xref>); <break/>(Li et&#x000a0;al., <xref ref-type="bibr" rid="CIT0066">2019</xref>);<break/>(Feng et&#x000a0;al., <xref ref-type="bibr" rid="CIT0034">2016</xref>)</td></tr><tr><td align="left">&#x02003;Raddeanin A</td><td align="left">Inhibit SRC/AKT signaling pathway;</td><td align="left">(Wang, Mo, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0129">2018</xref>)</td></tr><tr><td align="left">&#x02003;Platycodin D</td><td align="left">Blocked RANKL-induced osteoclast formation by inhibiting the expression and nuclear translocation of NFATc1 and c-Fos in BMMs; inhibited the growth of MDA-MB-231 cells</td><td align="left">(Lee et&#x000a0;al., <xref ref-type="bibr" rid="CIT0065">2015</xref>)</td></tr><tr><td align="left">&#x02003;wedelolactone</td><td align="left">Inhibit Akt/mammalian target of the rapamycin signaling pathway (mTOR); suppress NF-&#x003ba;B/c-fos/NFATc1 pathway</td><td align="left">(Hsieh et&#x000a0;al., <xref ref-type="bibr" rid="CIT0051">2015</xref>); <break/>(Liu, Hong, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0072">2016</xref>)</td></tr><tr><td align="left">&#x02003;Thymoquinone</td><td align="left">Suppress NF-KB and MAPK signaling</td><td align="left">(Thummuri et&#x000a0;al., <xref ref-type="bibr" rid="CIT0120">2015</xref>)</td></tr><tr><td align="left">&#x02003;Brucine</td><td align="left">Suppress Jagged1/Notch1 Signaling Pathways;<break/>Increase both the OPG mRNA/RANKL mRNA expression ratio and the OPG protein/RANKL protein ratio</td><td align="left">(Hu et&#x000a0;al., <xref ref-type="bibr" rid="CIT0052">2017</xref>); <break/>(Wu et&#x000a0;al., <xref ref-type="bibr" rid="CIT0139">2017</xref>)</td></tr><tr><td align="left">&#x02003;benzyl isothiocyanate</td><td align="left">Down-regulate RANKL and runt-related transcription factor 2 (RUNX2)</td><td align="left">(Pore et&#x000a0;al., <xref ref-type="bibr" rid="CIT0091">2018</xref>)</td></tr><tr><td align="left">&#x02003;Camellia sinensis</td><td align="left">Anti-oxidant</td><td align="left">(Luo et&#x000a0;al., <xref ref-type="bibr" rid="CIT0078">2015</xref>)</td></tr><tr><td align="left">&#x02003;Sinomenine</td><td align="left">Reducing IL-8/CXCR1 and c-Fos/NFATc1 signaling</td><td align="left">(Zhang, Zou, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0148">2019</xref>)</td></tr></tbody></table></table-wrap><p>Some traditional Chinese herb extractions were studied for their ability to inhibit the activation of osteoclast induced by cancer cells and obtained optimistic results, as showed in <xref rid="t0001" ref-type="table">Table 1</xref>. Curcumin, extraction from <italic>Curcuma longa</italic> plant, was able to anti-inflammatory and anti-cancer cells through NOTCH-1 signaling and suppress NF-&#x003ba;B relative gene expression. Artemisinin and its derivants, famous for curing malaria, were also researched about their inhibiting osteolysis and cancer ability. Dihydroartemisinin suppressed osteoclasts differentiation, F-actin ring formation, and bone resorption through AKT/SRC pathways. It also inhibited breast tumor-induced osteolysis by inhibiting the proliferation, migration and invasion of MDA-MB-231 cells via modulating AKT signaling pathway. Wedelolactone, a natural product from <italic>Ecliptae herba</italic>, was reported to be capable of suppressing breast cancer-induced osteoclastogenesis and enhancing osteoblastogenesis. And some extractions were revealed effective in suppressing osteoclasts formation and maturity without a clear mechanism yet. In spite of the satisfying experimental outcome, drugs&#x02019; low bioavailability, poor solubility, and short half-life limit their application (Wang, Sun, et&#x000a0;al., <xref rid="CIT0114" ref-type="bibr">2016</xref>).</p><p>In addition to the routine anticancer chemotherapeutic drug, photothermal agents (PTA) have aroused great interest of scientists because of their good photothermal conversion ability which is fundamental for the physical therapy of cancer.</p></sec><sec id="S0003-S2002" disp-level="2"><label>3.2.</label><title>Photothermal materials</title><p>NIR, which is absorbed in minimal amounts by water and biomolecules, can penetrate tissue deeply (Chen, Ning, et&#x000a0;al., <xref rid="CIT0016" ref-type="bibr">2019</xref>). First NIR window light (650&#x02013;950&#x02009;nm) is often utilized in photothermal therapy (PTT). Exposed to NIR radiation, PTA can generate heat through plasmon resonance or jump energy to rapidly increase the local temperature to ablate cancer cells. Cancer cells are more sensitive to heat than surrounding normal cells and more likely to be damaged with the cells membrane, intracellular protein, or RNA/DNA repair being broken (Abadeer &#x00026; Murphy, <xref rid="CIT0001" ref-type="bibr">2016</xref>). Regional hyperthermy can kill cells and increase the cells&#x02019; sensitivity to anticancer drugs (Sun, Ge, et&#x000a0;al., <xref rid="CIT0115" ref-type="bibr">2019</xref>). Frequently-used PTA include inorganic materials (noble metal materials, transition-metal chalcogenide materials, carbon-based nanomaterials etc.) and organic materials (polypyrrole and polydopamine, cyanine dyes, porphyrin, etc.). Gold NPs, Pt NPs, Fe<sub>3</sub>O<sub>4</sub> NPs, and carbon-based nanomaterials have been explored as PTA because of their effective photothermal conversion (Liu, Bhattarai, et&#x000a0;al., <xref rid="CIT0071" ref-type="bibr">2019</xref>; Zhao et&#x000a0;al., <xref rid="CIT0149" ref-type="bibr">2020</xref>). Polydopamine (PDA) is formed by mussel-inspired polymerization dopamine. PDA possesses not only versatile adhesion property (through covalent binding or non-covalent binding of catecholamine groups coordination or chelation) which can be utilized to modify the surface of various materials and bind drugs, high chemical activity, excellent biocompatibility, but also strong photothermal property. The biodegradable monodispersed bioactive glass (BGN) was modified by PDA and linked DOX to these NPs for enhancing colon cancer photothermo-chemotherapy and bone repair. NIR-excited PTT of BGN@PDA could ablate tumors. And the relative tumor volume was reduced to 0.85 in BGN@PDA-DOX group, 0.50 in BGN@PDA&#x02009;+&#x02009;NIR group, and 0.01 in BGN@PDA-DOX&#x02009;+&#x02009;NIR group after 12&#x000a0;d of treatment. <italic>In vivo</italic> experiment and quantitative analysis revealed that BGN@PDA and BGN could enhance new bone formation, and NIR did not reduce the bone regeneration efficacy of BGN@PDA (Xue et&#x000a0;al., <xref rid="CIT0140" ref-type="bibr">2020</xref>). In another study, the researcher fabricated a kind of ALN-conjugated PDA NPs (PDA-ALN), which exhibited excellent photothermal effect and high affinity to HA. PDA-ALN loaded anticancer drug 7-ethyl-10-hydroxycamptothecin (SN38) via &#x003c0;&#x02013;&#x003c0; stacking and the release of SN38 could be triggered by NIR. <xref ref-type="fig" rid="F0003">Figure 3(a)</xref> showed the mechanism of these multifunctional NPs. The combination of PTT (43&#x02009;&#x000b0;C) and chemotherapy in this smart and targeted delivery system suppressed the breast tumor&#x02019;s growth in bone and lessened the osteolytic destruction (<xref ref-type="fig" rid="F0003">Figure 3(b)</xref>; Wang, Huang, et&#x000a0;al., <xref rid="CIT0128" ref-type="bibr">2018</xref>).</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>(a) Illustration of bone-targeted NPs with chemo-photothermal treatment. (b) 3D micro-CT reconstruction image of the tumor-bearing tibias after several treatment (Wang, Huang, et&#x000a0;al., <xref rid="CIT0128" ref-type="bibr">2018</xref>).</p></caption><graphic content-type="color" xlink:href="IDRD_A_1856225_F0003_C"/></fig><p>Besides, some interesting photothermal materials with smart decoration were synthesized and applied in targeted delivery systems. Na<sub>x</sub>WO<sub>3</sub> NPs (about 150&#x02009;nm oxygen vacancy-rich tungsten bronze NPs) were synthesized for PTT. Na<sub>x</sub>WO<sub>3</sub> NPs had desirable PTT effects that the temperature increased from 25.8&#x02009;&#x000b0;C to 41.8&#x02009;&#x000b0;C in 5&#x02009;min under the irradiation of 980&#x02009;nm laser. The cytotoxicity of the particles against breast cancer cells appeared in dose-dependence <italic>in&#x000a0;vitro</italic>. In breast cancer models, Na<sub>x</sub>WO<sub>3</sub> + PTT group had the most effective inhibition of tumor and bone destruction (Jie et&#x000a0;al., <xref rid="CIT0055" ref-type="bibr">2019</xref>). Except for organic photothermal materials, noble metal and inorganic materials both have nonnegligible cytotoxicity, low biodegradability and low biocompatibility. Effective PTT needs the desired accumulation of PTA in the irradiated area. Thus, it is necessary to apply targeted or local drug delivery systems to carry these PTA to narrow their distribution and modify them to improve biocompatibility.</p></sec></sec><sec id="S0004" disp-level="1"><label>4.</label><title>Drug distribution optimization</title><sec id="S0004-S2001" disp-level="2"><label>4.1.</label><title>Targeted delivery</title><p>As just mentioned, anticancer treatment is the foundation of anti-metastatic osteolysis but inadequate without specific distribution in the osteolytic part or synergy with anti bone resorption drugs. Optimized targeted delivery systems usually rely on NPs which could target metastatic bone and carry anticancer or anti-osteolysis drugs efficiently via targeting ligands. <xref rid="t0002" ref-type="table">Table 2</xref> listed the collected targeted drug delivery systems. Through systemic administration methods like intravenous injection, targeted delivery systems narrow the drug&#x02019;s distribution to the bone, tumor, or osteolytic site. The ligands like BP, tetracycline, chelating compounds, salivary proteins, Alizarin Red S, and oligopeptides (oligo-aspartic acid) have an affinity to bone (de Miguel et&#x000a0;al., <xref rid="CIT0027" ref-type="bibr">2014</xref>; Chang et&#x000a0;al., <xref rid="CIT0012" ref-type="bibr">2016</xref>; Ryu et&#x000a0;al., <xref rid="CIT0100" ref-type="bibr">2016</xref>; Stapleton et&#x000a0;al., <xref rid="CIT0109" ref-type="bibr">2017</xref>). In the affinity assay for HA <italic>in&#x000a0;vitro</italic>, 77.5% of alendronate (ALN, Ald, or Alen) bound to HA powder (Ryu et&#x000a0;al., <xref rid="CIT0100" ref-type="bibr">2016</xref>). Zol exhibited 20-fold increased targeting of bone metastatic lesions than other major tissues (Hatami et&#x000a0;al., <xref rid="CIT0047" ref-type="bibr">2019</xref>). BP was used mostly to modify the designed NPs which encapsulated anticancer drugs. With BP, NPs can target bone and release anticancer drugs to inhibit cancer cells and suppress osteoclasts. Loaded drugs can be chemically conjugated to the nanocarriers or physically encapsulated or adsorbed and released by diffusion, erosion of carriers or the break of chemical bonds (Zeng et&#x000a0;al., <xref rid="CIT0145" ref-type="bibr">2019</xref>). The physicochemical property of these targeted nanocarriers makes a difference in their application (Danaei et&#x000a0;al., <xref rid="CIT0025" ref-type="bibr">2018</xref>). The size of nanocarriers cannot exceed 400&#x02009;nm in order to escape from macrophage and renal clearance and are preferably less than 200&#x02009;nm (Perez-Herrero &#x00026; Fernandez-Medarde, <xref rid="CIT0090" ref-type="bibr">2015</xref>). Smaller NPs can help them through the openings of the bone&#x02019;s sinusoidal capillaries (10&#x02013;70&#x02009;nm). Small neutral NPs (about 150&#x02009;nm) were also 7-fold more effective in localizing in bone marrow than large NPs (about 320&#x02009;nm; Adjei et&#x000a0;al., <xref rid="CIT0002" ref-type="bibr">2016</xref>). Nanocarriers between 70 and 100&#x02009;nm were often used to target bone for their extended blood circulating time (Adjei et&#x000a0;al., <xref rid="CIT0002" ref-type="bibr">2016</xref>). The nanocarriers with hydrophilic, neutral, or slightly anionic surfaces are more prone to localize in the bone marrow and escape from the macrophage attack by avoiding plasma proteins. A neutral surface charge is achieved by modulating the surface-associated emulsifier composition. Hydrophilic surface can be obtained by decoration with hydrophilic polymers like poly(ethylene glycol) (PEG) or amphiphilic polymers like synthetic copolymers of polyethylene oxide (hydrophilic block) and propylene oxide (hydrophobic block) (Perez-Herrero &#x00026; Fernandez-Medarde, <xref rid="CIT0090" ref-type="bibr">2015</xref>; Suk et&#x000a0;al., <xref rid="CIT0113" ref-type="bibr">2016</xref>). Targeted drug delivery systems have been developed based on polymer NPs, micelles, liposomes, Silica NPs, inorganic compounds (HA nanocrystal, calcium phosphates NPs, etc.), or organometallic compounds. Polymer NPs were used most frequently in drug release systems for their good biocompatibility and biodegradability and drugs were released through NPs erosion. Related synthetic polymers include polyglutamic acid, polyglycolic acid (PGA), PEG, polycaprolactone (PCL), polylactic acid (PLA), poly aspartate (PAA), poly(D, L-lactide-co-glycolic) acid (PLGA), and N-(2-hydroxypropyl)-methacrylamide copolymer (HPMA) Ulbrich et&#x000a0;al., <xref rid="CIT0122" ref-type="bibr">2016</xref>). Natural polymers include chitosan (CS), alginate, dextran, heparin, albumin, gelatin, and collagen (George et&#x000a0;al., <xref rid="CIT0042" ref-type="bibr">2019</xref>).</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Designed targeted drug delivery systems based on nanomaterials or nanotechnology and their release characteristics.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Classification</th><th align="center">Loaded drugs</th><th align="center">Ligand</th><th align="center">Target</th><th align="center">Trigger</th><th align="center">PTT</th><th align="center">Reference</th></tr></thead><tbody valign="top"><tr><td rowspan="3">MSNs</td><td align="left">DOX, ZOL</td><td align="left">ZOL</td><td align="left">Bone</td><td align="left">pH</td><td align="left">&#x000a0;</td><td align="left">(Sun, Han, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0116">2016</xref>)</td></tr><tr><td align="left">PL, ZOL</td><td align="left">ZOL</td><td align="left">Bone</td><td align="left">pH</td><td align="left">&#x000a0;</td><td align="left">(Qiao et&#x000a0;al., <xref ref-type="bibr" rid="CIT0094">2017</xref>)</td></tr><tr><td align="left">ZOL, Au</td><td align="left">ZOL</td><td align="left">Bone</td><td align="left">&#x000a0;</td><td align="left">Yes</td><td align="left">(Sun, Ge, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0115">2019</xref>)</td></tr><tr><td align="left">Calcium phosphate NPs</td><td align="left">MTX, ALN</td><td align="left">ALN</td><td align="left">Bone</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">(Chu et&#x000a0;al., <xref ref-type="bibr" rid="CIT0021">2017</xref>)</td></tr><tr><td rowspan="2">Liposome</td><td align="left">DOX</td><td align="left">Asp8, folate</td><td align="left">FR, bone</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">(Ke et&#x000a0;al., <xref ref-type="bibr" rid="CIT0059">2017</xref>)</td></tr><tr><td align="left">ALN, DOX</td><td align="left">ALN, hyaluronic acid</td><td align="left">CD44, bone</td><td align="left">Redox</td><td align="left">&#x000a0;</td><td align="left">(Feng et&#x000a0;al., <xref ref-type="bibr" rid="CIT0035">2019</xref>)</td></tr><tr><td align="left">nMOFs</td><td align="left">ZOL</td><td align="left">Folate</td><td align="left">FR</td><td align="left">pH</td><td align="left">&#x000a0;</td><td align="left">(Au et&#x000a0;al., <xref ref-type="bibr" rid="CIT0009">2016</xref>)</td></tr><tr><td align="left">Bioactive glass NPs</td><td align="left">DOX</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">pH, NIR</td><td align="left">Yes</td><td align="left">(Xue et&#x000a0;al., <xref ref-type="bibr" rid="CIT0140">2020</xref>)</td></tr><tr><td rowspan="4">Micelles</td><td align="left">ALN, curcumin</td><td align="left">ALN, Oligosaccharide of hyaluronan</td><td align="left">CD44, bone</td><td align="left">Redox</td><td align="left">&#x000a0;</td><td align="left">(Wang, Guo, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0127">2018</xref>)</td></tr><tr><td align="left">BTZ, ALN</td><td align="left">ALN</td><td align="left">Bone</td><td align="left">pH</td><td align="left">&#x000a0;</td><td align="left">(Zhu et&#x000a0;al., <xref ref-type="bibr" rid="CIT0153">2018</xref>)</td></tr><tr><td align="left">Docetaxel</td><td align="left">Quinolone nonpeptide</td><td align="left">IntegrinaV&#x003b2;3</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">(Ross et&#x000a0;al., <xref ref-type="bibr" rid="CIT0098">2017</xref>)</td></tr><tr><td align="left">DTX, ALN</td><td align="left">ALN</td><td align="left">Bone</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">(Liu, Romanova, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0073">2019</xref>)</td></tr><tr><td align="left">QD</td><td align="left">ALN, DOX</td><td align="left">ALN</td><td align="left">Bone</td><td align="left">pH</td><td align="left">&#x000a0;</td><td align="left">(Li et&#x000a0;al., <xref ref-type="bibr" rid="CIT0068">2017</xref>)</td></tr><tr><td align="left">Tungsten bronze nanoparticles</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Yes</td><td align="left">(Jie et&#x000a0;al., <xref ref-type="bibr" rid="CIT0055">2019</xref>)</td></tr><tr><td rowspan="8">Polymeric NP</td><td align="left">DOX, ALN</td><td align="left">ALN</td><td align="left">Bone</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">(Rudnick-Glick et&#x000a0;al., <xref ref-type="bibr" rid="CIT0099">2016</xref>)</td></tr><tr><td align="left">Cabazitaxel, ALN</td><td align="left">ALN</td><td align="left">Bone</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">(Gdowski et&#x000a0;al., <xref ref-type="bibr" rid="CIT0040">2017</xref>)</td></tr><tr><td align="left">ZOL</td><td align="left">ZOL</td><td align="left">Bone</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">(Hatami et&#x000a0;al., <xref ref-type="bibr" rid="CIT0047">2019</xref>)</td></tr><tr><td align="left">GANT58, ALN</td><td align="left">ALN</td><td align="left">Bone</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">(Vanderburgh et&#x000a0;al., <xref ref-type="bibr" rid="CIT0123">2020</xref>)</td></tr><tr><td align="left">DOX, ALN</td><td align="left">ALN, hyaluronic acid</td><td align="left">Bone, CD44</td><td align="left">pH, redox</td><td align="left">&#x000a0;</td><td align="left">(Zhao et&#x000a0;al., <xref ref-type="bibr" rid="CIT0150">2017</xref>)</td></tr><tr><td align="left">GANT58</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">ROS</td><td align="left">&#x000a0;</td><td align="left">(Vanderburgh et&#x000a0;al., <xref ref-type="bibr" rid="CIT0124">2019</xref>)</td></tr><tr><td align="left">PTX, ALN</td><td align="left">ALN, folate</td><td align="left">Bone, FR</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">(Chen et&#x000a0;al., <xref ref-type="bibr" rid="CIT0015">2020</xref>)</td></tr><tr><td align="left">SN38, ALN</td><td align="left">ALN</td><td align="left">Bone</td><td align="left">pH, NIR</td><td align="left">Yes</td><td align="left">(Wang, Huang, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0128">2018</xref>)</td></tr><tr><td rowspan="3">Dendrimer</td><td align="left">Pt NPs</td><td align="left">Carboxyl terminals</td><td align="left">Bone</td><td align="left">&#x000a0;</td><td align="left">Yes</td><td align="left">(Yan et&#x000a0;al., <xref ref-type="bibr" rid="CIT0141">2019</xref>)</td></tr><tr><td align="left">BTZ</td><td align="left">RGD</td><td align="left">IntegrinaV&#x003b2;3</td><td align="left">pH</td><td align="left">&#x000a0;</td><td align="left">(Wang, Cai, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0126">2018</xref>)</td></tr><tr><td align="left">DTX, ALN</td><td align="left">ALN, hyaluronic acid</td><td align="left">Bone, CD44</td><td align="left">pH, redox</td><td align="left">&#x000a0;</td><td align="left">(Bai et&#x000a0;al., <xref ref-type="bibr" rid="CIT0010">2019</xref>)</td></tr></tbody></table></table-wrap><sec id="S0004-S2001-S3001" disp-level="3"><label>4.1.1.</label><title>Mono target delivery</title><p>Most targeted NPs had only one kind of targeting ligands decorated to combine with one specific molecular structure in the osteolytic microenvironment. PLGA and cabazitaxel were used as the core with amino-BP surface conjugation to make NPs. Bone-targeted NPs showed an 8-fold affinity to the bone in 72&#x02009;h compared with non-targeted NPs. After one-month treatment of bone metastatic models, only the targeted NPs treatment group had a significant reduction in limb weight and pain response. And targeted NPs provided all treated mice protection from bone lesions while 33% of the mice with nontargeted NPs treatment had bone lesions (Gdowski et&#x000a0;al., <xref rid="CIT0040" ref-type="bibr">2017</xref>). Similarly, polymeric NPs or micelles encapsulating anticancer drugs, functionalized with ZA or ALN for homing bone, were designed in many other studies and demonstrated much higher efficiency and accumulation in bone than free drugs (Rudnick-Glick et&#x000a0;al., <xref rid="CIT0099" ref-type="bibr">2016</xref>; Hatami et&#x000a0;al., <xref rid="CIT0047" ref-type="bibr">2019</xref>; Liu, Romanova, et&#x000a0;al., <xref rid="CIT0073" ref-type="bibr">2019</xref>). A novel preparation of polymeric NPs with high affinity to bone was completed by Yuya Hirano et&#x000a0;al. (Hirano &#x00026; Iwasaki, <xref rid="CIT0048" ref-type="bibr">2017</xref>). Two-step synthesis of cholesteryl-functionalized poly(ethylene sodium phosphate) (Ch-PEPn&#x000b7;Na) was performed via ring-opening polymerization of cyclic phosphoesters and the demethylation. Synthesized PEPn&#x000b7;Na NPs adsorbed onto HA with the help of poly(ethylene sodium phosphate) which is an analog of polyphosphoesters and has a polyphosphodiester backbone. Scanning electron microscopy images demonstrated PEPn&#x000b7;Na NPs had a higher affinity to the bone than PEG NPs. In addition to polymeric NPs, calcium phosphate NPs and multi-walled carbon nanotubes were also utilized as BP-modified drug delivery systems to target bone (Chu et&#x000a0;al., <xref rid="CIT0021" ref-type="bibr">2017</xref>; Dlamini et&#x000a0;al., <xref rid="CIT0029" ref-type="bibr">2019</xref>). It was reported that carboxyl groups on the dendrimer surface endowed dendrimer with the intrinsic bone-binding affinity (Yan et&#x000a0;al., <xref rid="CIT0141" ref-type="bibr">2019</xref>). The dendrimer loaded with Pt NPs (DEPt-COOH) showed a high affinity to HA and bone fragments <italic>in&#x000a0;vitro</italic> and was able to selectively recognize the osteolytic bone lesions <italic>in&#x000a0;vivo</italic> (Yan et&#x000a0;al., <xref rid="CIT0141" ref-type="bibr">2019</xref>). Polyphosphate (polyP) was also used in a bone-targeted system. Ca-polyP nano/microparticles complexed with ZA maintained the morphogenesis and mineralization-inducing activity of polyP and anti-osteolysis effect of BP (M&#x000fc;ller et&#x000a0;al., <xref rid="CIT0082" ref-type="bibr">2018</xref>). Optimized PTT systems usually depended on targeted NPs or locally implanted materials to increase PTT efficiency and reduce the toxicity to other organs because PTA are hard to degrade. For example, Gold nanorods were enclosed inside targeted mesoporous silica NPs (MSNs NPs) for PTT and obtained obvious treatment effects (Sun, Ge, et&#x000a0;al., <xref rid="CIT0115" ref-type="bibr">2019</xref>).</p></sec><sec id="S0004-S2001-S3002" disp-level="3"><label>4.1.2.</label><title>Dual target delivery</title><p>BP modified drug delivery systems targeted both healthy and destructed bones no matter whether cancer metastasis happened. Adding the targets of delivery systems is an effective way to improve the accuracy of targeting. For instance, designed NPs may contain two types of target ligands that target bone and tumor cells respectively. Dual-targeted or even multi-targeted drug delivery systems rely on the discovery of cells&#x02019; special expression or special molecular structure in the osteolytic microenvironment. It was found that bone metastatic cancer cells overexpress folate receptor (FR), cluster of differentiation 44 (CD44) and integrin &#x003b1;V&#x003b2;3. Human cells express and depend on FR to uptake exogenous folate. FR is widely expressed in normal and tumor cells but more in quantity and activity in tumor cells. In tumor cells, FR loses polarity and becomes easier for drugs in circulation to approach. Folate is a target ligand for FR and is often used to modify the targeted NPs synergistically with BP to target metastatic bone lesions (Assaraf et&#x000a0;al., <xref rid="CIT0008" ref-type="bibr">2014</xref>; Au et&#x000a0;al., <xref rid="CIT0009" ref-type="bibr">2016</xref>). Shih-Hong Chen et&#x000a0;al. designed an NPs-based dual-targeted delivery system comprising hydrophobic PLGA core and ALN-modified, folic acid-conjugated D-a-tocopheryl polyethylene glycol succinate (TPGS) coat to deliver PTX. PTX-loaded dual-targeted NPs evidently accumulated in bone metastases after intravenous injection and exhibited the highest efficiency of inhibiting 4T1 tumor growth. It retarded bone destruction of the tumor-bearing mice appreciably with significant improvement of the survival rate of treated mice (median survival &#x0003e;50&#x000a0;d, but &#x0003c;35&#x000a0;d in other groups; Chen et&#x000a0;al., <xref rid="CIT0015" ref-type="bibr">2020</xref>). In another work, aspartate which possesses affinity to the bone because of the similar HA-binding domain of osteopontin and osteocalcin, and folate were used to conjugate onto the surface of DOX-loaded liposomes. Fluorescent images (<xref ref-type="fig" rid="F0004">Figure 4</xref>) demonstrated that dual-targeted liposomes optimized the liposome accumulation in cancer metastatic bone (Ke et&#x000a0;al., <xref rid="CIT0059" ref-type="bibr">2017</xref>). CD44 is one kind of transmembrane glycoprotein that binds with extracellular matrix hyaluronic acid to mediate intracellular signaling. It is overexpressed in tumor cells and plays an important role in tumor metastasis and invasion. Hyaluronic acid, as a specific ligand for CD44 receptor, was used in many targeted delivery systems (Dosio et&#x000a0;al., <xref rid="CIT0031" ref-type="bibr">2016</xref>; Bai et&#x000a0;al., <xref rid="CIT0010" ref-type="bibr">2019</xref>). Kaili Wang et&#x000a0;al. fabricated CD44 and bone dual-targeted nano micelles via a series of esterification reactions, with oligosaccharides of hyaluronan targeting CD44 and ALN targeting bone. <italic>In vivo</italic> distribution experience, dual-targeted micelles group had higher distribution to the bone than other groups (Wang, Guo, et&#x000a0;al., <xref rid="CIT0127" ref-type="bibr">2018</xref>). Another work about DOX-loaded bone and CD44-dual-targeted delivery system showed that the signals of dual-targeting group peaked at 2&#x02009;h after injection, quicker than the CD44-single-targeting group (6&#x02009;h). The median survival time was extended to 67&#x000a0;d from 30&#x000a0;d for the untreated group (Feng et&#x000a0;al., <xref rid="CIT0035" ref-type="bibr">2019</xref>). These results showed that dual-targeted delivery systems have a stronger ability to target metastatic bone, further optimized the distribution of drugs. Integrin &#x003b1;V&#x003b2;3 is expressed rarely in normal cells but highly in tumor cells and neoplastic neovascular endothelial cells. It can activate matrix metalloproteinase 2 (MMP-2) and accelerate tumor cells secreting cell adherence molecule which contributes to tumor metastasis and neoplastic neovascular formation. ITG&#x003b2;3 (a subunit of integrin &#x003b1;V&#x003b2;3) is over-expressed in bone metastatic cancer cells compared to cancer cells from other metastatic organs such as liver, lymph nodes (Ross et&#x000a0;al., <xref rid="CIT0098" ref-type="bibr">2017</xref>; Gdowski et&#x000a0;al., <xref rid="CIT0039" ref-type="bibr">2019</xref>). ITG&#x003b2;3 is a critical factor that contributes to the ability of cancer cells to specifically home and bind to endothelial cells in bone (Kwakwa &#x00026; Sterling, <xref rid="CIT0063" ref-type="bibr">2017</xref>). This targeting bone function of integrin was exploited to engineer a programmable-bioinspired NPs (P-BiNP) to target bone and increase uptake in homotypic tumor cells (Gdowski et&#x000a0;al., <xref rid="CIT0039" ref-type="bibr">2019</xref>). Researchers employed chemokine factor motif chemokine ligand 12 (CXCL12) to stimulate cancer cells to express more integrin, and purified cancer cell membranes to carry PLGA NPs. <italic>In vivo</italic> bone homing experiment, P-BiNP had an increased affinity to the bone and decreased affinity to other organs compared to the BiNPs (Gdowski et&#x000a0;al., <xref rid="CIT0039" ref-type="bibr">2019</xref>). On the other hand, integrin &#x003b1;V&#x003b2;3 can be a target and recognized by tripeptide Arg&#x02009;&#x02212;&#x02009;Gly&#x02009;&#x02212;&#x02009;Asp (RGD) and quinolone nonpeptide specifically (Wang, Cai, et&#x000a0;al., <xref rid="CIT0126" ref-type="bibr">2018</xref>). Michael H. Ross et&#x000a0;al. used quinolone nonpeptide to decorate phospholipid/polysorbate-80 micelle NPs which loaded DOX and demonstrated a stronger accumulation in bone metastases than nontargeted NPs through immunofluorescent analysis <italic>in&#x000a0;vivo</italic> (Ross et&#x000a0;al., <xref rid="CIT0098" ref-type="bibr">2017</xref>). Well-design and mature technology are required for linking two kinds of ligands to nanocarriers. And whether dual-targeted systems could have better biodistribution still needs to be experimented.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Biodistribution of various liposomes containing Cy5.5 in mice bearing MDA-MB-231 tumors determined by an IVIS Spectrum-CT (Ke et&#x000a0;al., <xref rid="CIT0059" ref-type="bibr">2017</xref>).</p></caption><graphic content-type="color" xlink:href="IDRD_A_1856225_F0004_C"/></fig></sec></sec><sec id="S0004-S2002" disp-level="2"><label>4.2.</label><title>Local delivery</title><p>Through the systemic administration, targeted NPs arrive at the destination with the help of the bloodstream. The degradation and drug release of miss-targeted particles may impact the liver or kidney consequently (Chew &#x00026; Danti, <xref rid="CIT0020" ref-type="bibr">2017</xref>). However, the implanted drug-loading materials deliver drugs directly and locally in implanted position, escaping the &#x02018;danger&#x02019; in the bloodstream without facing the blood marrow barrier. Some studies revealed that bone metastasis models treated with locally administered ZA obtained a statistically significant increase in bone volume/tissue volume compared with treatment with systemic ZA administration (Nooh et&#x000a0;al., <xref rid="CIT0084" ref-type="bibr">2017</xref>; Ahangar et&#x000a0;al., <xref rid="CIT0003" ref-type="bibr">2018</xref>). Local drug delivery systems can further improve drugs&#x02019; curative efficiency. These systems rely on implantable biomaterials and implantation operation, maximize the therapy efficiency of drugs, and minimize the toxicity to other organs (Newman &#x00026; Benoit, <xref rid="CIT0083" ref-type="bibr">2016</xref>). They can reduce the frequency of drug administration because of a large number of drugs loaded and more sustained release, but run the risk of infection and inflammation after implantation (Sarigol-Calamak &#x00026; Hascicek, <xref rid="CIT0105" ref-type="bibr">2018</xref>). When the tumors in bone marrow develop and cause bone destruction, the operation is necessary. After tumor resection, bone grafts are always implanted as a substitute for destroyed bone (Chen, Boda, et&#x000a0;al., <xref rid="CIT0013" ref-type="bibr">2018</xref>), but not enough to inhibit ongoing osteolysis and residual cancer cell proliferation. Therefore, these implanted materials can be modified as multifunctional local drug delivery systems to prevent further bone resorption in subsequent therapy and as bone grafts for the support of the bone function. The implantable materials for lessening osteolysis mainly included scaffolds and porous composite that need to be surgically implanted and locally injected self-assembly hydrogel. Titanium, polymers, calcium phosphate, CS, collagen, hyaluronic acid, alginate were commonly used to fabricate or modify these implantable materials. Solid-state processing (powder metallurgy, sintering of powders and fibers), liquid state processing (direct foaming and spray foaming), vapor deposition, and electrode position were exploited to fabricate porous materials (Sarigol-Calamak &#x00026; Hascicek, <xref rid="CIT0105" ref-type="bibr">2018</xref>). 3D-print technology (Do et&#x000a0;al., <xref rid="CIT0030" ref-type="bibr">2015</xref>; Wang et&#x000a0;al., <xref rid="CIT0132" ref-type="bibr">2020</xref>) and electrospinning (Chen, Boda, et&#x000a0;al., <xref rid="CIT0013" ref-type="bibr">2018</xref>) were also employed to fabricate 3D multifunctional scaffolds (Yu et&#x000a0;al., <xref rid="CIT0143" ref-type="bibr">2016</xref>). Porosity, biodegradability, swelling, and mechanical property of materials have an effect on local drug delivery manner (Chen, Boda, et&#x000a0;al., <xref rid="CIT0013" ref-type="bibr">2018</xref>; Wu et&#x000a0;al., <xref rid="CIT0136" ref-type="bibr">2018</xref>).</p><sec id="S0004-S2002-S3001" disp-level="3"><label>4.2.1.</label><title>Implantable scaffold or composite</title><p>The most common way to optimize the grafts for treating osteolysis is decorating them with anti-osteolysis drugs. For example, ZOL-loaded bone cement or tricalcium phosphate (TCP) inhibited malignant bone tumors or metastatic bone tumors with the help of sustained ZOL release and acted as a bone substitute at the same time (Koto et&#x000a0;al., <xref rid="CIT0061" ref-type="bibr">2017</xref>; Rahmanian et&#x000a0;al., <xref rid="CIT0095" ref-type="bibr">2017</xref>). Aliphatic polyesters like PCL, PLA, PLLA were used widely for their good biodegradability, biocompatibility, and permeability (Oledzka et&#x000a0;al., <xref rid="CIT0087" ref-type="bibr">2017</xref>). Ewa Oledzka et&#x000a0;al. prepared a new multifunctional composite as a promising bone substitute material in which HA porous granules doped with selenite ions (SeO<sub>3</sub><sup>2&#x02212;</sup>) and conjugated biodegradable branched copolymer-BP. This composite delivered pamidronate locally to inhibit bone resorption and osteoclast activity. The different molar ratios of copolymers (PLLA/PCL) resulted in different drug release kinetics and degradation speed (Oledzka et&#x000a0;al., <xref rid="CIT0087" ref-type="bibr">2017</xref>). In another work, PCL matrix and multilayer polyelectrolyte were combined to fabricate a scaffold in which CaCO<sub>3</sub> microparticles were covered with multilayer polyelectrolyte and then loaded with dexamethasone (DXM) for sustained local release. As a drug delivery system, this PCL scaffold also promoted osteoblast-like cells (Palam&#x000e0; et&#x000a0;al., <xref rid="CIT0089" ref-type="bibr">2017</xref>). 3D-print technology is popular in medicine and bionics. It has been used extensively in fabricating individualistic, multifunctional scaffolds and given the inspiration to design local drug release systems. In the work of Pouyan Ahangar et&#x000a0;al., 3D-printed scaffolds which loaded and locally delivered DOX to inhibit cancer cells could also potentially serve as a substitute for destructed bone tissue (Ahangar et&#x000a0;al., <xref rid="CIT0003" ref-type="bibr">2018</xref>). Commonly applied for the repair and replacement of bone in the clinic, titanium is often utilized to fabricate 3D bone scaffolds in researches (Wang et&#x000a0;al., 2019). Kun Zhang et&#x000a0;al. fabricated a 3D-printed multifunctional titanium scaffold with an anti-tumor function via modification of locally-released nHA. After 5&#x02009;weeks of implantation, <italic>in-situ</italic> tumor volume of the rabbit implanted with nHA/titanium scaffold was 73.8% smaller than other groups. Micro-CT showed nHA/titanium scaffold inhibited osteolytic destruction (<xref ref-type="fig" rid="F0005">Figure 5(a)</xref>). New bone formed at the pore walls of the nHA/titanium scaffold (<xref ref-type="fig" rid="F0005">Figure 5(b))</xref> (Zhang, Zhou, et&#x000a0;al., <xref rid="CIT0148" ref-type="bibr">2019</xref>). Another optimized implantable titanium scaffold was fabricated with titania nanotube arrays to form nano-engineered 3D titanium wire. TNF-related apoptosis-inducing ligand (TRAIL) was loaded onto titania nanotube arrays (Ti-TNT) to form TRAIL-TNTs for localized cancer treatment (Song et&#x000a0;al., <xref rid="CIT0108" ref-type="bibr">2018</xref>). The mechanical property and microstructure of TRAIL-TNTs made it proper to support bone and act as a substitute graft with local treatment after cancer resection. Type I collagen and calcium salt are the main ingredients of bone. Thus, composites containing some similar nature polymers and calcium salt possess good biocompatibility and outstanding ability to induce osteogenesis. Mehdi Rahmanian et&#x000a0;al. developed a gelatin/beta-TCP (&#x003b2;-TCP) nanocomposite scaffold loaded with ZA for bone defect regeneration and local drug release after cancer resection. Porous structure (50&#x02013;200&#x02009;&#x003bc;m pore) of gelatin reinforced with &#x003b2;-TCP spherical NPs (around 90&#x02009;nm diameter) facilitated bone cell proliferation. Local ZA release not only inhibited the residual cancer cells and osteoclasts but also promoted osteoblasts proliferation. Histopathological results showed that the new bone formation was established by more than 75% in the whole area of the defect after 3 and 4&#x02009;months (Rahmanian et&#x000a0;al., <xref rid="CIT0096" ref-type="bibr">2019</xref>). PTT can collaborate with implantable scaffold logically and naturally. Fe<sub>3</sub>O<sub>4</sub> NPs and hydrated GdPO<sub>4</sub> nanorods were incorporated in bioactive CS matrix to form multifunctional GdPO<sub>4</sub>/CS/Fe<sub>3</sub>O<sub>4</sub> scaffolds for tumor PTT and bone tissue regeneration. The Fe<sub>3</sub>O<sub>4</sub> NPs improved NIR absorption capacity and photothermal conversion efficiency. After 10&#x02009;min of NIR laser irradiation, the temperature of GdPO<sub>4</sub>/CS/Fe<sub>3</sub>O<sub>4</sub> scaffolds arrived at 47.7&#x02009;&#x000b0;C and the local temperature around the GdPO<sub>4</sub>/CS/Fe<sub>3</sub>O<sub>4</sub> scaffolds arrived up to 45.4&#x02009;&#x000b0;C within 20&#x02009;s. The tumor diameter in GdPO<sub>4</sub>/CS/Fe<sub>3</sub>O<sub>4</sub> treatment group decreased with the therapy time extension. Hydrated GdPO<sub>4</sub> nanorods served as a novel bioactive component for enhancing angiogenesis and osteogenesis. The scaffolds also promoted the osteogenic related gene expression and bone regeneration (Zhao et&#x000a0;al., <xref rid="CIT0149" ref-type="bibr">2020</xref>). Multifunctional scaffolds have certain mechanical properties and space structures and these make them only apply to the severe metastatic bone defect area which need surgery.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>(a) Micro-CT&#x02013;reconstructed images of the implants and adjacent bone tissue. B: bone; S: scaffold; arrows show adjacent cortical bone resorption by tumor. (b) Histological observation of the implanted scaffolds. S: scaffold; T: tumor; red arrows indicate new bone formation (Zhang, Zhou, et&#x000a0;al., <xref rid="CIT0147" ref-type="bibr">2019</xref>).</p></caption><graphic content-type="color" xlink:href="IDRD_A_1856225_F0005_C"/></fig></sec><sec id="S0004-S2002-S3002" disp-level="3"><label>4.2.2.</label><title>Injectable hydrogel</title><p>Injectable drug delivery systems for treating osteolysis mainly include particle and hydrogel. Hydrogel materials incorporated with drugs and NPs have been explored as local delivery systems. The designed injectable hydrogel can solidify with certain environmental conditions. They were supposed to solidify at about 37&#x02009;&#x000b0;C through molecular self-assembly. It is conceivable that injectable hydrogel materials have much weaker mechanical properties than implanted scaffolds and this makes hydrogel inferior to scaffolds as bone substitutes. These materials achieved local delivery through simple local injection, not implant surgery. They were also employed for cancer treatment by many researchers (Norouzi et&#x000a0;al., <xref rid="CIT0085" ref-type="bibr">2016</xref>). For treating osteolysis, pamidronate (Pami)-derivative and Alen-derivative hydrogelators Pami-D and Alen-D were used to form supramolecular hydrogels under acidic conditions. Pami-D and Alen-D inhibited the proliferation and osteoclastogenesis of bone marrow-derived macrophages in a dose-dependent manner <italic>in&#x000a0;vitro</italic> (Tang et&#x000a0;al., <xref rid="CIT0119" ref-type="bibr">2016</xref>). This design enriched the application of BP in the realm of the hydrogel. Injectable hydrogel materials, possessing the property of sustained release, are good drug carriers for treating some diseases with low requirement of the mechanical property.</p></sec></sec></sec><sec id="S0005" disp-level="1"><label>5.</label><title>Drug release optimization</title><sec id="S0005-S2001" disp-level="2"><label>5.1.</label><title>Responsive release</title><p>Stimulus-responsive drug delivery systems based on nanocarriers can be triggered by pH, enzymatic catalysis, magnetic, thermal, ultrasonic, electric, and irradiation stimuli (Liu, Yang, et&#x000a0;al., <xref rid="CIT0074" ref-type="bibr">2016</xref>; Saravanakumar et&#x000a0;al., <xref rid="CIT0104" ref-type="bibr">2017</xref>; Jain et&#x000a0;al., <xref rid="CIT0054" ref-type="bibr">2018</xref>). Smart delivery systems for treating osteolysis can be activated by the osteolytic microenvironment such as low pH, high concentration of calcium, and active redox reaction to release drugs responsively (Karimi et&#x000a0;al., <xref rid="CIT0057" ref-type="bibr">2016</xref>; Tan et&#x000a0;al., <xref rid="CIT0118" ref-type="bibr">2016</xref>; Bai et&#x000a0;al., <xref rid="CIT0010" ref-type="bibr">2019</xref>). Designed pH-sensitive delivery systems release drugs through protonation or deprotonation of groups (carboxylic acid group, amino group) or break of chemical bonds (hydrazone, acetal, cis-Aconityl, &#x003b2;-thiopropionate, etc.) in an acidic environment. Aryl boronate group, as an acid&#x02013;labile linker, was employed to construct pH-sensitive delivery systems. Mingming Wang et&#x000a0;al. made polyamidoamine (PAMAM) dendrimer with catechol and PEG ligands modification (Wang, Cai, et&#x000a0;al., <xref rid="CIT0126" ref-type="bibr">2018</xref>). Boronate-catechol linkage was pH-responsive and linked bortezomib (BTZ) to dendrimer for responsive BTZ delivery to low pH. BTZ was released from the polymer less than 5% at pH 7.4 at 12&#x02009;h but nearly 57% at pH 5.0 at 6&#x02009;h. PH 5.0 is usually known as the lysosomal pH (pH 4.5) (Wang, Cai, et&#x000a0;al., <xref rid="CIT0126" ref-type="bibr">2018</xref>). A similar design was made by Jianhua Zhu et&#x000a0;al. (Zhu et&#x000a0;al., <xref rid="CIT0153" ref-type="bibr">2018</xref>). In a study, Zol-anchored MSNs (DOX@MSNs&#x02009;&#x02212;&#x02009;ZOL) loaded DOX and had obvious pH-sensitive DOX release behavior because MSNs&#x02009;&#x02212;&#x02009;ZOL did not have enough hydroxyl radicals to create hydrogen bond with the amino group of DOX. DOX@MSNs&#x02009;&#x02212;&#x02009;ZOL entered cells through an ATP-dependent pathway and then localized in the lysosome to achieve effective intracellular DOX release (Chen, Boda, et&#x000a0;al., <xref rid="CIT0013" ref-type="bibr">2018</xref>). Chunyan Li et&#x000a0;al. fabricated a Ag<sub>2</sub>S QD-based nanosystem (Ald/DOX@Ag<sub>2</sub>S) with surface-anchored ALN and encapsulated DOX (<xref ref-type="fig" rid="F0006">Figure 6(a)</xref>). These NPs were deposited in bone tissues and then DOX was released in the tumor site triggered by the acidic tumor microenvironment. The drug release kinetics was exhibited in <xref ref-type="fig" rid="F0006">Figure 6(b)</xref>. Ald/DOX@Ag<sub>2</sub>S caused a time and dose-dependent increase in caspase-3 activity (apoptosis assay) and inhibited the osteoclastic differentiation of RAW264.7 cells stimulated by RANKL (Li et&#x000a0;al., <xref rid="CIT0068" ref-type="bibr">2017</xref>). Likewise, redox acted as a trigger in some targeted delivery systems because of the active redox at the osteolytic site. Glutathione (GSH) is an antioxidant and its concentration is 7&#x02013;10 times higher in tumor cells than normal cells (1&#x02013;10&#x02009;mmol L<sup>&#x02212;1</sup>) (Wu et&#x000a0;al., <xref rid="CIT0137" ref-type="bibr">2004</xref>; Aluri et&#x000a0;al., <xref rid="CIT0005" ref-type="bibr">2009</xref>; Wang et&#x000a0;al., <xref rid="CIT0133" ref-type="bibr">2014</xref>). Disulfide bonds can be broken by GSH so that it was utilized by many scientists to fabricate micelles or polymeric NPs in response to the active redox. J.P. Vanderburgh et&#x000a0;al. developed aqueous and intravenously injectable micellar NPs to encapsulate GANT58 via a combination of anionic and reversible addition-fragmentation chain transfer (RAFT) polymerization. Poly[(oligo ethylene glycol)<sub>9</sub> methyl ether acrylate]<sub>17</sub> formed the hydrophilic NPs surface while polymer poly(propylene sulfide) formed the hydrophobic core that sequestered GANT58. In response to reactive oxygen species (ROS), poly(propylene sulfide) became hydrophilic and degraded to initiate drug release. In an intratibia breast cancer bone metastasis model, these NPs decreased bone lesion area and lesion number by 49% and 38% respectively, and increased trabecular bone volume (Vanderburgh et&#x000a0;al., <xref rid="CIT0124" ref-type="bibr">2019</xref>). Stimulus-release systems also can be triggered by two or more stimuli. Metal-organic frameworks (MOFs), mainly in a cubic shape, with an average size &#x0003c;100&#x02009;nm in diameter, were utilized to construct a multi-stimuli &#x02018;gated scaffold.&#x02019; The frameworks based on zirconium, remained tightly and controlled release at the normal Ca<sup>2+</sup> concentration, pH, and temperature, but released drugs around/in bone tumor cells with increasing Ca<sup>2+</sup> concentration, decreasing pH, and/or by using thermal therapy. During this process, carboxylatopillar[5]arene played a vital role in regulating the binding between the rings-structure and the stalk-structure (Tan et&#x000a0;al., <xref rid="CIT0118" ref-type="bibr">2016</xref>). Multi-stimuli responsive systems are more sensitive to the osteolytic microenvironment and deliver the drug more rapidly but less specifically. It may be optimized through integration with implantable materials or targeted NPs. Another NPs, DOX@ALN-(HA-PASP)CL, were prepared with pH sensitivity and redox sensitivity. During the synthesis of these NPs, ALN and HA were linked by a hydrazone bond which was responsive to the acidic microenvironment. HA and PASP [poly(aspartic acid)] were cross-linked by a disulfide bond to increase the stability of the NPs. Release kinetics of DOX from DOX@ALN-(HA-PASP)CL was showed in <xref ref-type="fig" rid="F0006">Figure 6(c)</xref>. Tumor and bone resorption was inhibited obviously in the research (Zhao et&#x000a0;al., <xref rid="CIT0150" ref-type="bibr">2017</xref>). The responsive delivery embodied the prevention theory. But if osteolysis already happened, stimulus-release aimed to reduce the drug release of miss-targeted NPs to further reduce the side effects and accelerate the drug release in the osteolytic microenvironment.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>(a) Schematic representation of Ald/DOX@Ag<sub>2</sub>S for bone tumor therapy; (b) Release kinetics of DOX from Ald/DOX@Ag<sub>2</sub>S over time in PBS at pH 5 and 7.4, respectively (Li et&#x000a0;al., <xref rid="CIT0068" ref-type="bibr">2017</xref>). (c) Release kinetics of DOX from DOX@ALN-(HA-PASP)CL, GSH (glutathione), DTT (dithiothreitol) (Zhao et&#x000a0;al., <xref rid="CIT0150" ref-type="bibr">2017</xref>).</p></caption><graphic content-type="color" xlink:href="IDRD_A_1856225_F0006_C"/></fig></sec><sec id="S0005-S2002" disp-level="2"><label>5.2.</label><title>Sustained release</title><p>In local delivery systems based on implanted materials, drug loading can be obtained by the following methods: (a). mixing drugs with materials directly before fabrication; (b). entrapping drugs into basic drug carriers (e.g. NPs) and adding this system to implantable materials; (c). immersing scaffold/hydrogel/composite into drugs solution; (d). anchoring drug on the materials (physical adsorption, chemical conjunction); (e). coating the scaffold in a polymer or composite solution (Sarigol-Calamak &#x00026; Hascicek, <xref rid="CIT0105" ref-type="bibr">2018</xref>). Drugs can be released from implantable materials in several ways, such as drug diffusion, drug adsorption&#x02013;desorption, and materials erosion (Chen, Boda, et&#x000a0;al., <xref rid="CIT0013" ref-type="bibr">2018</xref>). The early-stage release always appears a burst release through diffusion followed by a constant release through materials erosion or further diffusion (Zeng et&#x000a0;al., <xref rid="CIT0145" ref-type="bibr">2019</xref>). Biodegradable materials are degraded by hydrolysis and enzymolysis (Song et&#x000a0;al., <xref rid="CIT0108" ref-type="bibr">2018</xref>). When NPs serve as drug carriers and then are incorporated in implantable materials or modify the materials, special properties of NPs can endow the implantable materials with new merits, such as stimulus-release ability, photothermal property, and more sustained release ability. GG-NPs-ALN system, with ALN-loaded PLGA NPs carried in the matrix of gellan gum, was injectable and delivered ALN intra-bone in a constant manner. The ALN release graphs of NPs-ALN and GG-NPs-ALN are shown in <xref ref-type="fig" rid="F0007">Figure 7</xref>. It was obvious that this local release system released drugs more slowly and constantly. GG-NPs-ALN was cytocompatible with osteoblast-like cells but inhibited RANKL mediated osteoclastic differentiation of RAW 264.7 cells significantly <italic>in&#x000a0;vitro</italic> (Posadowska et&#x000a0;al., <xref rid="CIT0092" ref-type="bibr">2015</xref>). Liposomes were often incorporated in hydrogel materials (Ding et&#x000a0;al., <xref rid="CIT0028" ref-type="bibr">2016</xref>; Wu et&#x000a0;al., <xref rid="CIT0136" ref-type="bibr">2018</xref>). Wei Wu et&#x000a0;al. designed a local release system (GEM-Lip@Gel) based on hydrogel, in which liposomes blended with methacryloyl (GelMA). Gemcitabine (GEM) was loaded into liposomes for local release to kill osteosarcoma cells. GEM-Lip@Gel (with liposome) had a more constant level than GEM-GelMA (without liposome) in drug release assay and showed the strongest ability to inhibit cancer cells than the control <italic>in&#x000a0;vitro</italic> and <italic>in&#x000a0;vivo</italic> (Wu et&#x000a0;al., <xref rid="CIT0136" ref-type="bibr">2018</xref>). <xref rid="t0003" ref-type="table">Table 3</xref> outlined some local delivery systems of lessening bone destruction and their drug-release characteristics. A sustained release can be realized easily by biodegradable materials like hydrogels. Biodegradable materials release drugs sustainedly through erosion and it is controllable through regulating the matrix ingredient ratio, crosslinking method, or utilizing NPs which encapsulate drugs.</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>ALN release curves from drug-loaded NPs (a) and gellan gum based injectable system (b). Cumulative curves (black squares and lines) as well as doses released from 1&#x02009;ml of NPs-ALN suspension (1% w/v) or 1&#x02009;ml of GG&#x02013;NPs-ALN system during 5&#x000a0;d intervals (boxes) are shown (Posadowska et&#x000a0;al., <xref rid="CIT0092" ref-type="bibr">2015</xref>).</p></caption><graphic content-type="color" xlink:href="IDRD_A_1856225_F0007_C"/></fig><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Designed local release systems based on nanomaterials or nanotechnology and the released characteristics.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Classification</th><th align="center">Matrix</th><th align="center">Fabrication methods</th><th align="center">Loaded drug</th><th align="center">Osteogenesis</th><th align="center">PTT</th><th align="center">Trigger</th><th align="center">50% cumulative release time</th><th align="center">Reference</th></tr></thead><tbody valign="top"><tr><td rowspan="8" align="left">Scaffold composite</td><td align="left">Titanium</td><td align="left">3D print; slurry foaming method</td><td align="left">HA NPs</td><td align="left">Yes</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x0003e;7&#x000a0;d</td><td align="left">(Zhang, Zhou, et&#x000a0;al., <xref ref-type="bibr" rid="CIT0148">2019</xref>)</td></tr><tr><td align="left">Thermoplastic polyurethane (TPU) copolymer with polyvinyl alcohol</td><td align="left">3D print</td><td align="left">DOX</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x0223c;1&#x000a0;d</td><td align="left">(Ahangar et&#x000a0;al., <xref ref-type="bibr" rid="CIT0003">2018</xref>)</td></tr><tr><td align="left">PCL</td><td align="left">Solvent casting and particulate leaching technique</td><td align="left">Dexamethasone</td><td align="left">Yes</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x0003e;192&#x02009;h</td><td align="left">(Palam&#x000e0; et&#x000a0;al., <xref ref-type="bibr" rid="CIT0089">2017</xref>)</td></tr><tr><td align="left">Titania</td><td align="left">Electrochemical method</td><td align="left">TRAIL</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x0003e;4&#x000a0;d</td><td align="left">(Kaur et&#x000a0;al., <xref ref-type="bibr" rid="CIT0058">2016</xref>)</td></tr><tr><td align="left">Hydroxyapatite granules and branched copolymer-pamidronate</td><td align="left">Copolymerization</td><td align="left">Pamidronate</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Bis-MPA-PLLA90-PCL38 &#x02009;&#x0003e;&#x02009;20h;bis-MPA -PLLA64-PCL64,bis-MPA -PLLA38-PCL90&#x02009;&#x0003e;&#x02009;120h</td><td align="left">(Oledzka et&#x000a0;al., <xref ref-type="bibr" rid="CIT0087">2017</xref>)</td></tr><tr><td align="left">Gelatin/(&#x003b2;-TCP) nanocomposite</td><td align="left">Cross-linking and self-assemble</td><td align="left">ZOL</td><td align="left">yes</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">(Rahmanian et&#x000a0;al., <xref ref-type="bibr" rid="CIT0095">2017</xref>)</td></tr><tr><td align="left">Hydroxyapatite (HA) and polymethyl methacrylate (PMMA) bone cement</td><td align="left">Polymerization</td><td align="left">ZOL</td><td align="left">Yes</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">(Koto et&#x000a0;al., <xref ref-type="bibr" rid="CIT0061">2017</xref>)</td></tr><tr><td align="left">CS</td><td align="left">Freeze-drying</td><td align="left">&#x000a0;</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">(Zhao et&#x000a0;al., <xref ref-type="bibr" rid="CIT0149">2020</xref>)</td></tr><tr><td rowspan="4" align="left">Hydrogel</td><td align="left">Pluronic</td><td align="left">Cold method</td><td align="left">Bleomycin A6</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x0223c;8&#x02009;h</td><td align="left">(Ding et&#x000a0;al., <xref ref-type="bibr" rid="CIT0028">2016</xref>)</td></tr><tr><td align="left">Gelatin methacryloyl</td><td align="left"><italic toggle="yes">In-situ</italic> photocrosslinkable</td><td align="left">Gemcitabine</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x0003c;&#x0223c;12&#x02009;h</td><td align="left">(Wu et&#x000a0;al., <xref ref-type="bibr" rid="CIT0136">2018</xref>)</td></tr><tr><td align="left">Gellan gum</td><td align="left">Cross-linking and reassemble</td><td align="left">ALN</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x0003e;25&#x000a0;d</td><td align="left">(Posadowska et&#x000a0;al., <xref ref-type="bibr" rid="CIT0092">2015</xref>)</td></tr><tr><td align="left">Pami-D; Alen-D</td><td align="left">Self-assemble</td><td align="left">Pami-D; Alen-D</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">(Tang et&#x000a0;al., <xref ref-type="bibr" rid="CIT0119">2016</xref>)</td></tr></tbody></table></table-wrap></sec></sec><sec id="S0006" disp-level="1"><label>6.</label><title>The prospect</title><sec id="S0006-S2001" disp-level="2"><label>6.1.</label><title>Multifunctional nanomaterials</title><p>The optimization in this review does not merely focus on drug distribution and release manner but also emphasizes the design of multifunctional materials. Utilizing nanotechnology to realize inhibiting cancer cells and osteoclasts simultaneously is a great optimization and improvable. When metastatic bone destruction occurs, it is not enough to anti-cancer and anti bone resorption, promoting bone regeneration is also important to improve the quality of life. In tissue engineering and regenerative medicine, many implantable biomaterials have been designed with good biocompatibility and osteoconductive ability to promote bone tissue regeneration (Sarigol-Calamak &#x00026; Hascicek, <xref rid="CIT0105" ref-type="bibr">2018</xref>; Martin &#x00026; Bettencourt, <xref rid="CIT0081" ref-type="bibr">2018</xref>). Calcium phosphate (Lee et&#x000a0;al., <xref rid="CIT0064" ref-type="bibr">2016</xref>), CS (Kozusko et&#x000a0;al., <xref rid="CIT0062" ref-type="bibr">2018</xref>), collagen (Cruz-Neves et&#x000a0;al., <xref rid="CIT0024" ref-type="bibr">2017</xref>), hyaluronic acid, nHA (Cruz-Neves et&#x000a0;al., <xref rid="CIT0024" ref-type="bibr">2017</xref>), polymers (Olthof et&#x000a0;al., <xref rid="CIT0088" ref-type="bibr">2018</xref>; Sarigol-Calamak &#x00026; Hascicek, <xref rid="CIT0105" ref-type="bibr">2018</xref>), metal and some composites (Newman &#x00026; Benoit, <xref rid="CIT0083" ref-type="bibr">2016</xref>) were often used to fabricate bionic scaffolds with osteogenesis drugs, factors or even cells carried on, like bone morphogenetic protein-2 (BMP-2) (Holzapfel et&#x000a0;al., <xref rid="CIT0049" ref-type="bibr">2016</xref>; Lee et&#x000a0;al., <xref rid="CIT0064" ref-type="bibr">2016</xref>; Martin &#x00026; Bettencourt, <xref rid="CIT0081" ref-type="bibr">2018</xref>; Olthof et&#x000a0;al., <xref rid="CIT0088" ref-type="bibr">2018</xref>). These implanted bone tissue engineering or bone regeneration materials can be explored as multifunctional materials to carry anti-osteolysis drugs or anti-osteolysis drug delivery systems. Multifunctional materials also are characterized by multi drugs and multi delivery systems. The integration of different drugs and different systems (target delivery systems, PTT systems, local delivery systems) can be realized by tactfully designed nanomaterials and novel fabrication nanotechnology. During the treatment of osteolysis, reducing bone pain is another therapy goal. Designed materials should also be tested for their bone pain alleviating ability, such as mechanical allodynia and thermal hyperalgesia test on cancer metastasis model (De Felice et&#x000a0;al., <xref rid="CIT0026" ref-type="bibr">2016</xref>; Wei et&#x000a0;al., <xref rid="CIT0135" ref-type="bibr">2017</xref>; Zhou, Chen, et&#x000a0;al., <xref rid="CIT0151" ref-type="bibr">2017</xref>).</p></sec><sec id="S0006-S2002" disp-level="2"><label>6.2.</label><title>Gene therapy</title><p>Gene therapy aims at regulating cells&#x02019; apoptosis and function at the level of genes to treat disease. Most cancer-related gene therapy introduced exogenous DNA segments or delivered siRNA or miRNA into target cells to regulate DNA expression (Fitzgerald et&#x000a0;al., <xref rid="CIT0036" ref-type="bibr">2016</xref>; Wang, Yu, et&#x000a0;al., <xref rid="CIT0134" ref-type="bibr">2016</xref>; Lima et&#x000a0;al., <xref rid="CIT0069" ref-type="bibr">2019</xref>). Till November 2017, almost 2600 gene therapy clinical trials had been completed and about 85% of these trials used a virus as vectors or naked/plasmid DNA (Ginn et&#x000a0;al., <xref rid="CIT0044" ref-type="bibr">2018</xref>). However, The clinic applications are limited because of the drawbacks of nucleic acids. The free nucleic acid in blood could be degraded by various cells (reticuloendothelial system, mononuclear phagocyte system) and biomolecules (nucleases). The size of plasmid DNA could hinder it into cells (Zhou, Liu, et&#x000a0;al., <xref rid="CIT0152" ref-type="bibr">2017</xref>). Several non-viral vectors were fabricated to deliver nucleic acid, including cationic polymers like polylysine (PLL), poly(ethyleneimine) (PEI), PAMAM, PEG, CS, cationic lipids (Chen, Yue, et&#x000a0;al., <xref rid="CIT0019" ref-type="bibr">2018</xref>), inorganic NPs (gold, silica, iron oxide and quantum dot) (Zhou, Liu, et&#x000a0;al., <xref rid="CIT0152" ref-type="bibr">2017</xref>). In many types of research, gene therapy cooperated with PTT to anti-cancer relying on nano delivery systems (Kim et&#x000a0;al., <xref rid="CIT0060" ref-type="bibr">2016</xref>; Wang, Yu, et&#x000a0;al., <xref rid="CIT0134" ref-type="bibr">2016</xref>; Chu et&#x000a0;al., <xref rid="CIT0022" ref-type="bibr">2019</xref>). Knockdown of BMPR1a in breast cancer cells through Adenovirus-mediated RNA interference was reported to suppress the production of RANKL via p38 pathway and inhibit cancer-induced osteoclast genesis (Liu et&#x000a0;al., <xref rid="CIT0075" ref-type="bibr">2018</xref>). However, few delivery systems of optimizing gene delivery to stop the &#x02018;vicious circle&#x02019; were available. Actually, the aforementioned nanomaterials or nanotechnology can be applied to optimize the relevant DNA/RNA delivery to hinder osteolysis.</p><p>Exosomes are a hot topic recently. Exosomes are lipid bilayer vesicles containing miRNA and protein. They are produced and excreted from cells to regulate cells&#x02019; action and are also explored as drug carriers (Ha et&#x000a0;al., <xref rid="CIT0046" ref-type="bibr">2016</xref>; Bellavia et&#x000a0;al., <xref rid="CIT0011" ref-type="bibr">2018</xref>).</p><p>In osteolysis, some miRNAs play a very important role in regulating bone destruction. MiR-31, miR-33a, miR-34a, miR-133a, miR-141, miR-155, miR-190, miR-192, miR-219, and miR-223 were reported to be capable of influencing osteoclast differentiation in bone metastasis (Ell et&#x000a0;al., <xref rid="CIT0033" ref-type="bibr">2013</xref>; Kagiya, <xref rid="CIT0056" ref-type="bibr">2015</xref>). A hydrogel-embedded, gold-NPs-based delivery vehicle provided efficient local, selective, and sustained release of miR-96/miR-182, markedly suppressed metastasis in a breast cancer mouse model (Gilam et&#x000a0;al., <xref rid="CIT0043" ref-type="bibr">2016</xref>). Implantable nanomaterials and targeted NPs may provide new ways for applying miRNA or exosome to cure osteolysis.</p></sec></sec></body><back><sec id="S0007" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><ref-list><title>References</title><ref id="CIT0001"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abadeer</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>CJ.</given-names></name></person-group> (<year>2016</year>). <article-title>Recent progress in cancer thermal therapy using gold nanoparticles</article-title>. <source>J Phys Chem C</source>
<volume>120</volume>:<fpage>4691</fpage>&#x02013;<lpage>716</lpage>.</mixed-citation></ref><ref id="CIT0002"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adjei</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Peetla</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer</article-title>. <source>J Controlled Release</source>
<volume>232</volume>:<fpage>83</fpage>&#x02013;<lpage>92</lpage>.</mixed-citation></ref><ref id="CIT0003"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahangar</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Akoury</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Luna</surname><given-names>ASRG</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Nanoporous 3D-printed scaffolds for local doxorubicin delivery in bone metastases secondary to prostate cancer</article-title>. <source>Materials</source>
<volume>11</volume>:<fpage>1485</fpage>.</mixed-citation></ref><ref id="CIT0004"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahangar</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Aziz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rosenzweig</surname><given-names>DH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Advances in personalized treatment of metastatic spine disease</article-title>. <source>Ann Transl Med</source>
<volume>7</volume>:<fpage>223</fpage>.<pub-id pub-id-type="pmid">31297388</pub-id></mixed-citation></ref><ref id="CIT0005"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aluri</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Janib</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Mackay</surname><given-names>JA.</given-names></name></person-group> (<year>2009</year>). <article-title>Environmentally responsive peptides as anticancer drug carriers</article-title>. <source>Adv Drug Deliv Rev</source>
<volume>61</volume>:<fpage>940</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">19628014</pub-id></mixed-citation></ref><ref id="CIT0006"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>YH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Curcumin inhibits polyethylene-induced osteolysis via repressing NF-&#x003ba;B signaling pathway activation</article-title>. <source>Cell Physiol Biochem</source>
<volume>50</volume>:<fpage>1100</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">30355954</pub-id></mixed-citation></ref><ref id="CIT0007"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrade</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fornetti</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>RON kinase: a target for treatment of cancer-induced bone destruction and osteoporosis</article-title>. <source>Sci Transl Med</source>
<volume>9</volume>:<fpage>eaai9338</fpage>.<pub-id pub-id-type="pmid">28123075</pub-id></mixed-citation></ref><ref id="CIT0008"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assaraf</surname><given-names>YG</given-names></name>, <name name-style="western"><surname>Leamon</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>JA.</given-names></name></person-group> (<year>2014</year>). <article-title>The folate receptor as a rational therapeutic target for personalized cancer treatment</article-title>. <source>Drug Resist Updat</source>
<volume>17</volume>:<fpage>89</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">25457975</pub-id></mixed-citation></ref><ref id="CIT0009"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Au</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Satterlee</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Min</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: turning a bone antiresorptive agent into an anticancer therapeutic</article-title>. <source>Biomaterials</source>
<volume>82</volume>:<fpage>178</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">26763733</pub-id></mixed-citation></ref><ref id="CIT0010"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>S-b</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>D-z</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Osteoclasts and tumor cells dual targeting nanoparticle to treat bone metastases of lung cancer</article-title>. <source>Nanomed-Nanotechnol Biol Med</source>
<volume>21</volume>:<fpage>102054</fpage>.</mixed-citation></ref><ref id="CIT0011"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellavia</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Raimondi</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Costa</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Engineered exosomes: a new promise for the management of musculoskeletal diseases</article-title>. <source>Biochim Biophys Acta Gen Subj</source>
<volume>1862</volume>:<fpage>1893</fpage>&#x02013;<lpage>901</lpage>.<pub-id pub-id-type="pmid">29885361</pub-id></mixed-citation></ref><ref id="CIT0012"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Geng</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting</article-title>. <source>Drug Deliv</source>
<volume>23</volume>:<fpage>3629</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">27749106</pub-id></mixed-citation></ref><ref id="CIT0013"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Boda</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Batra</surname><given-names>SK</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Emerging roles of electrospun nanofibers in cancer research</article-title>. <source>Adv Healthcare Mater</source>
<volume>7</volume>:<fpage>1701024</fpage>.</mixed-citation></ref><ref id="CIT0014"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>He</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>In vivo SELEX of bone targeting aptamer in prostate cancer bone metastasis model</article-title>. <source>Int J Nanomedicine</source>
<volume>14</volume>:<fpage>149</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">30613143</pub-id></mixed-citation></ref><ref id="CIT0015"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>TI</given-names></name>, <name name-style="western"><surname>Chuang</surname><given-names>CL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2020</year>). <article-title>Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer</article-title>. <source>J Mater Chem B</source>
<volume>8</volume>:<fpage>3789</fpage>&#x02013;<lpage>800</lpage>.<pub-id pub-id-type="pmid">32150202</pub-id></mixed-citation></ref><ref id="CIT0016"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>JQ</given-names></name>, <name name-style="western"><surname>Ning</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>ZN</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Nanomaterials as photothermal therapeutic agents</article-title>. <source>Prog Mater Sci</source>
<volume>99</volume>:<fpage>1</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">30568319</pub-id></mixed-citation></ref><ref id="CIT0017"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>XH</given-names></name>, <name name-style="western"><surname>Pei</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Exploring the molecular mechanism associated with breast cancer bone metastasis using bioinformatic analysis and microarray genetic interaction network</article-title>. <source>Medicine</source>
<volume>97</volume>:<fpage>e12032</fpage>.<pub-id pub-id-type="pmid">30212931</pub-id></mixed-citation></ref><ref id="CIT0018"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name></person-group> (<year>2019</year>). <article-title>Bioinspired and biomimetic nanomedicines</article-title>. <source>Acc Chem Res</source>
<volume>52</volume>:<fpage>1255</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">30977635</pub-id></mixed-citation></ref><ref id="CIT0019"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yue</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lei</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Promoter-operating targeted expression of gene therapy in cancer: current stage and prospect</article-title>. <source>Mol Ther Nucleic Acids</source>
<volume>11</volume>:<fpage>508</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">29858085</pub-id></mixed-citation></ref><ref id="CIT0020"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chew</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Danti</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Biomaterial-based implantable devices for cancer therapy</article-title>. <source>Adv Healthcare Mater</source>
<volume>6</volume>:<fpage>1600766</fpage>.</mixed-citation></ref><ref id="CIT0021"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Calcium phosphate nanoparticles functionalized with alendronate-conjugated polyethylene glycol (PEG) for the treatment of bone metastasis</article-title>. <source>Int J Pharm</source>
<volume>516</volume>:<fpage>352</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">27887884</pub-id></mixed-citation></ref><ref id="CIT0022"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Zinc(II)-dipicolylamine coordination nanotheranostics: toward synergistic nanomedicine by combined photo/gene therapy</article-title>. <source>Angew Chem Int Ed Engl</source>
<volume>58</volume>:<fpage>269</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">30421488</pub-id></mixed-citation></ref><ref id="CIT0023"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Croucher</surname><given-names>PI</given-names></name>, <name name-style="western"><surname>McDonald</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>TJ.</given-names></name></person-group> (<year>2016</year>). <article-title>Bone metastasis: the importance of the neighbourhood</article-title>. <source>Nat Rev Cancer</source>
<volume>16</volume>:<fpage>373</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">27220481</pub-id></mixed-citation></ref><ref id="CIT0024"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruz-Neves</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Graca</surname><given-names>I</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Behavior of prostate cancer cells in a nanohydroxyapatite/collagen bone scaffold</article-title>. <source>J Biomed Mater Res A</source>
<volume>105</volume>:<fpage>2035</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">28371333</pub-id></mixed-citation></ref><ref id="CIT0025"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danaei</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dehghankhold</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ataei</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems</article-title>. <source>Pharmaceutics</source>
<volume>10</volume>:<fpage>57</fpage>.</mixed-citation></ref><ref id="CIT0026"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Felice</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lambert</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Holen</surname><given-names>I</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Effects of Src-kinase inhibition in cancer-induced bone pain</article-title>. <source>Mol Pain</source>
<volume>12</volume>:<fpage>174480691664372</fpage>.</mixed-citation></ref><ref id="CIT0027"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Miguel</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Noiray</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Surpateanu</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2014</year>). <article-title>Poly(&#x003b3;-benzyl-L-glutamate)-PEG-alendronate multivalent nanoparticles for bone targeting</article-title>. <source>Int J Pharm</source>
<volume>460</volume>:<fpage>73</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">24211357</pub-id></mixed-citation></ref><ref id="CIT0028"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Bleomycin A6-loaded anionic liposomes with in situ gel as a new antitumoral drug delivery system</article-title>. <source>Drug Deliv</source>
<volume>23</volume>:<fpage>88</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">24845479</pub-id></mixed-citation></ref><ref id="CIT0029"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dlamini</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Mukaya</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>Van Zyl</surname><given-names>RL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Synthesis, characterization, kinetic drug release and anticancer activity of bisphosphonates multi-walled carbon nanotube conjugates</article-title>. <source>Mater Sci Eng C-Mater Biol Appl</source>
<volume>104</volume>:<fpage>109967</fpage>.<pub-id pub-id-type="pmid">31499981</pub-id></mixed-citation></ref><ref id="CIT0030"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Do</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Khorsand</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Geary</surname><given-names>SM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2015</year>). <article-title>3D printing of scaffolds for tissue regeneration applications</article-title>. <source>Adv Healthc Mater</source>
<volume>4</volume>:<fpage>1742</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">26097108</pub-id></mixed-citation></ref><ref id="CIT0031"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dosio</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Arpicco</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Stella</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Hyaluronic acid for anticancer drug and nucleic acid delivery</article-title>. <source>Adv Drug Deliv Rev</source>
<volume>97</volume>:<fpage>204</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">26592477</pub-id></mixed-citation></ref><ref id="CIT0032"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duong</surname><given-names>LT</given-names></name>, <name name-style="western"><surname>Wesolowski</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Leung</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2014</year>). <article-title>Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis</article-title>. <source>Mol Cancer Ther</source>
<volume>13</volume>:<fpage>2898</fpage>&#x02013;<lpage>909</lpage>.<pub-id pub-id-type="pmid">25249554</pub-id></mixed-citation></ref><ref id="CIT0033"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ell</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Mercatali</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ibrahim</surname><given-names>T</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2013</year>). <article-title>Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis</article-title>. <source>Cancer Cell</source>
<volume>24</volume>:<fpage>542</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">24135284</pub-id></mixed-citation></ref><ref id="CIT0034"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>M-X</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>J-X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts</article-title>. <source>Sci Rep</source>
<volume>6</volume>:<fpage>19074</fpage>.<pub-id pub-id-type="pmid">26743690</pub-id></mixed-citation></ref><ref id="CIT0035"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Z-X</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Engineering of bone- and CD44-dual-targeting redox-sensitive liposomes for the treatment of orthotopic osteosarcoma</article-title>. <source>ACS Appl Mater Interfaces</source>
<volume>11</volume>:<fpage>7357</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">30682240</pub-id></mixed-citation></ref><ref id="CIT0036"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fitzgerald</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Raftery</surname><given-names>RM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Nanoparticle-mediated siRNA delivery assessed in a 3D co-culture model simulating prostate cancer bone metastasis</article-title>. <source>Int J Pharm</source>
<volume>511</volume>:<fpage>1058</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">27492023</pub-id></mixed-citation></ref><ref id="CIT0037"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forte</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Torricelli</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Boanini</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Quercetin and alendronate multi-functionalized materials as tools to hinder oxidative stress damage</article-title>. <source>J Biomed Mater Res A</source>
<volume>105</volume>:<fpage>3293</fpage>&#x02013;<lpage>303</lpage>.<pub-id pub-id-type="pmid">28865182</pub-id></mixed-citation></ref><ref id="CIT0038"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Futakuchi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fukamachi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Suzui</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Heterogeneity of tumor cells in the bone microenvironment: mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer</article-title>. <source>Adv Drug Deliv Rev</source>
<volume>99</volume>:<fpage>206</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">26656603</pub-id></mixed-citation></ref><ref id="CIT0039"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gdowski</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Lampe</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>VJT</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Bioinspired nanoparticles engineered for enhanced delivery to the bone</article-title>. <source>ACS Appl Nano Mater</source>
<volume>2</volume>:<fpage>6249</fpage>&#x02013;<lpage>57</lpage>.</mixed-citation></ref><ref id="CIT0040"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gdowski</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Ranjan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sarker</surname><given-names>MR</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain</article-title>. <source>Nanomedicine</source>
<volume>12</volume>:<fpage>2083</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">28805551</pub-id></mixed-citation></ref><ref id="CIT0041"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>YW</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>XL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2020</year>). <article-title>Quercetin inhibits macrophage polarization through the p-38&#x003b1;/&#x003b2; signalling pathway and regulates OPG/RANKL balance in a mouse skull model</article-title>. <source>J Cell Mol Med</source>
<volume>24</volume>:<fpage>3203</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">32053272</pub-id></mixed-citation></ref><ref id="CIT0042"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>George</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Shrivastav</surname><given-names>PS.</given-names></name></person-group> (<year>2019</year>). <article-title>Natural biodegradable polymers based nano-formulations for drug delivery: a review</article-title>. <source>Int J Pharm</source>
<volume>561</volume>:<fpage>244</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">30851391</pub-id></mixed-citation></ref><ref id="CIT0043"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilam</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Conde</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Weissglas-Volkov</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Local microRNA delivery targets palladin and prevents metastatic breast cancer</article-title>. <source>Nat Commun</source>
<volume>7</volume>:<fpage>12868</fpage>.<pub-id pub-id-type="pmid">27641360</pub-id></mixed-citation></ref><ref id="CIT0044"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ginn</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Amaya</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Alexander</surname><given-names>IE</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Gene therapy clinical trials worldwide to 2017: an update</article-title>. <source>J Gene Med</source>
<volume>20</volume>:<fpage>e3015</fpage>.<pub-id pub-id-type="pmid">29575374</pub-id></mixed-citation></ref><ref id="CIT0045"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gul</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Sendur</surname><given-names>MAN</given-names></name>, <name name-style="western"><surname>Aksoy</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>A comprehensive review of denosumab for bone metastasis in patients with solid tumors</article-title>. <source>Curr Med Res Opin</source>
<volume>32</volume>:<fpage>133</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">26451465</pub-id></mixed-citation></ref><ref id="CIT0046"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ha</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>NN</given-names></name>, <name name-style="western"><surname>Nadithe</surname><given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges</article-title>. <source>Acta Pharm Sin B</source>
<volume>6</volume>:<fpage>287</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">27471669</pub-id></mixed-citation></ref><ref id="CIT0047"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatami</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Nagesh</surname><given-names>PKB</given-names></name>, <name name-style="western"><surname>Chowdhury</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Development of zoledronic acid-based nanoassemblies for bone-targeted anticancer therapy</article-title>. <source>ACS Biomater Sci Eng</source>
<volume>5</volume>:<fpage>2343</fpage>&#x02013;<lpage>54</lpage>.</mixed-citation></ref><ref id="CIT0048"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirano</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Iwasaki</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Bone-specific poly(ethylene sodium phosphate)-bearing biodegradable nanoparticles</article-title>. <source>Colloids Surf B Biointerfaces</source>
<volume>153</volume>:<fpage>104</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">28231498</pub-id></mixed-citation></ref><ref id="CIT0049"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holzapfel</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Wagner</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Martine</surname><given-names>LC</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Tissue engineering and regenerative medicine in musculoskeletal oncology</article-title>. <source>Cancer Metastasis Rev</source>
<volume>35</volume>:<fpage>475</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">27566370</pub-id></mixed-citation></ref><ref id="CIT0050"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horne</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Mihov</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Reid</surname><given-names>IR.</given-names></name></person-group> (<year>2018</year>). <article-title>Bone loss after romosozumab/denosumab: effects of bisphosphonates</article-title>. <source>Calcif Tissue Int</source>
<volume>103</volume>:<fpage>55</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">29445836</pub-id></mixed-citation></ref><ref id="CIT0051"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>C-J</given-names></name>, <name name-style="western"><surname>Kuo</surname><given-names>P-L</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>M-F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2015</year>). <article-title>Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling</article-title>. <source>Int J Oncol</source>
<volume>46</volume>:<fpage>555</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">25421824</pub-id></mixed-citation></ref><ref id="CIT0052"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>K-f</given-names></name>, <name name-style="western"><surname>Kong</surname><given-names>X-y</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>M-c</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Brucine inhibits bone metastasis of breast cancer cells by suppressing jagged1/notch1 signaling pathways</article-title>. <source>Chin J Integr Med</source>
<volume>23</volume>:<fpage>110</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">28035539</pub-id></mixed-citation></ref><ref id="CIT0053"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irelli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cocciolone</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Cannita</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer</article-title>. <source>Bone</source>
<volume>87</volume>:<fpage>169</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">27091227</pub-id></mixed-citation></ref><ref id="CIT0054"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tiwari</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Verma</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Ultrasound-based triggered drug delivery to tumors</article-title>. <source>Drug Deliv Transl Res</source>
<volume>8</volume>:<fpage>150</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">29204925</pub-id></mixed-citation></ref><ref id="CIT0055"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jie</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Ouyang</surname><given-names>Z.</given-names></name></person-group> (<year>2019</year>). <article-title>Tumor ablation using novel photothermal NaxWO3 nanoparticles against breast cancer osteolytic bone metastasis</article-title>. <source>Int J Nanomedicine</source>
<volume>14</volume>:<fpage>7353</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">31571856</pub-id></mixed-citation></ref><ref id="CIT0056"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kagiya</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>MicroRNAs and osteolytic bone metastasis: the roles of MicroRNAs in tumor-induced osteoclast differentiation</article-title>. <source>J Clin Med</source>
<volume>4</volume>:<fpage>1741</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">26343739</pub-id></mixed-citation></ref><ref id="CIT0057"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karimi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ghasemi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zangabad</surname><given-names>PS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems</article-title>. <source>Chem Soc Rev</source>
<volume>45</volume>:<fpage>1457</fpage>&#x02013;<lpage>501</lpage>.<pub-id pub-id-type="pmid">26776487</pub-id></mixed-citation></ref><ref id="CIT0058"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Willsmore</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gulati</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Titanium wire implants with nanotube arrays: a study model for localized cancer treatment</article-title>. <source>Biomaterials</source>
<volume>101</volume>:<fpage>176</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">27289379</pub-id></mixed-citation></ref><ref id="CIT0059"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ke</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Synergistic dual-modified liposome improves targeting and therapeutic efficacy of bone metastasis from breast cancer</article-title>. <source>Drug Deliv</source>
<volume>24</volume>:<fpage>1680</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">29092646</pub-id></mixed-citation></ref><ref id="CIT0060"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jeong</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Synergistic nanomedicine by combined gene and photothermal therapy</article-title>. <source>Adv Drug Deliv Rev</source>
<volume>98</volume>:<fpage>99</fpage>&#x02013;<lpage>112</lpage>.<pub-id pub-id-type="pmid">26748259</pub-id></mixed-citation></ref><ref id="CIT0061"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Murata</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sawai</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors</article-title>. <source>Oncol Lett</source>
<volume>14</volume>:<fpage>1648</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">28789391</pub-id></mixed-citation></ref><ref id="CIT0062"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kozusko</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Riccio</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Goulart</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Chitosan as a bone scaffold biomaterial</article-title>. <source>J Craniofac Surg</source>
<volume>29</volume>:<fpage>1788</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">30157141</pub-id></mixed-citation></ref><ref id="CIT0063"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwakwa</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Sterling</surname><given-names>JA.</given-names></name></person-group> (<year>2017</year>). <article-title>Integrin alpha v beta 3 signaling in tumor-induced bone disease</article-title>. <source>Cancers</source>
<volume>9</volume>:<fpage>84</fpage>.</mixed-citation></ref><ref id="CIT0064"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>E-U</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>H-C</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>J-Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Bone regenerative efficacy of biphasic calcium phosphate collagen composite as a carrier of rhBMP-2</article-title>. <source>Clin Oral Implants Res</source>
<volume>27</volume>:<fpage>e91</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25675839</pub-id></mixed-citation></ref><ref id="CIT0065"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>K-K</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H-J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2015</year>). <article-title>Platycodin D blocks breast cancer-induced bone destruction by inhibiting osteoclastogenesis and the growth of breast cancer cells</article-title>. <source>Cell Physiol Biochem</source>
<volume>36</volume>:<fpage>1809</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">26184636</pub-id></mixed-citation></ref><ref id="CIT0066"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Artemisinin inhibits breast cancer-induced osteolysis by inhibiting osteoclast formation and breast cancer cell proliferation</article-title>. <source>J Cell Physiol</source>
<volume>234</volume>:<fpage>12663</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">30536376</pub-id></mixed-citation></ref><ref id="CIT0067"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2012</year>). <article-title>Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment</article-title>. <source>Curr Mol Med</source>
<volume>12</volume>:<fpage>967</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">22574935</pub-id></mixed-citation></ref><ref id="CIT0068"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Engineered multifunctional nanomedicine for simultaneous stereotactic chemotherapy and inhibited osteolysis in an orthotopic model of bone metastasis</article-title>. <source>Adv Mater</source>
<volume>29</volume>:<fpage>1605754</fpage>.</mixed-citation></ref><ref id="CIT0069"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lima</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Ferreira</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Reis</surname><given-names>RL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Biodegradable polymers: an update on drug delivery in bone and cartilage diseases</article-title>. <source>Expert Opin Drug Deliv</source>
<volume>16</volume>:<fpage>795</fpage>&#x02013;<lpage>813</lpage>.<pub-id pub-id-type="pmid">31220958</pub-id></mixed-citation></ref><ref id="CIT0070"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipton</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fizazi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Stopeck</surname><given-names>AT</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics</article-title>. <source>Eur J Cancer</source>
<volume>53</volume>:<fpage>75</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">26693901</pub-id></mixed-citation></ref><ref id="CIT0071"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Bhattarai</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>ZF</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer</article-title>. <source>Chem Soc Rev</source>
<volume>48</volume>:<fpage>2053</fpage>&#x02013;<lpage>108</lpage>.<pub-id pub-id-type="pmid">30259015</pub-id></mixed-citation></ref><ref id="CIT0072"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y-Q</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>Z-L</given-names></name>, <name name-style="western"><surname>Zhan</surname><given-names>L-B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Wedelolactone enhances osteoblastogenesis by regulating Wnt/beta-catenin signaling pathway but suppresses osteoclastogenesis by NF-kappa B/c-fos/NFATc1 pathway</article-title>. <source>Sci Rep</source>
<volume>6</volume>:<fpage>32260</fpage>.<pub-id pub-id-type="pmid">27558652</pub-id></mixed-citation></ref><ref id="CIT0073"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Romanova</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Alendronate-modified polymeric micelles for the treatment of breast cancer bone metastasis</article-title>. <source>Mol Pharm</source>
<volume>16</volume>:<fpage>2872</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">31150251</pub-id></mixed-citation></ref><ref id="CIT0074"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Xiong</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>The smart drug delivery system and its clinical potential</article-title>. <source>Theranostics</source>
<volume>6</volume>:<fpage>1306</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">27375781</pub-id></mixed-citation></ref><ref id="CIT0075"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>R-X</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>W</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Knockdown of bone morphogenetic proteins type 1a receptor (BMPR1a) in breast cancer cells protects bone from breast cancer-induced osteolysis by suppressing RANKL expression</article-title>. <source>Cell Physiol Biochem</source>
<volume>45</volume>:<fpage>1759</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">29495003</pub-id></mixed-citation></ref><ref id="CIT0076"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Mu</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2011</year>). <article-title>VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging &#x003b1;4&#x003b2;1-positive osteoclast progenitors</article-title> . <source>Cancer Cell</source>
<volume>20</volume>:<fpage>701</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">22137794</pub-id></mixed-citation></ref><ref id="CIT0077"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>QQ</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>GH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2009</year>). <article-title>ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis</article-title>. <source>Genes &#x00026; Development</source>
<volume>23</volume>:<fpage>1882</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">19608765</pub-id></mixed-citation></ref><ref id="CIT0078"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>KW</given-names></name>, <name name-style="western"><surname>Ko</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Yue</surname><given-names>GGL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2015</year>). <article-title>The combined use of <italic>Camellia sinensis</italic> and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model</article-title>. <source>J Cancer Res Clin Oncol</source>
<volume>141</volume>:<fpage>1025</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">25431338</pub-id></mixed-citation></ref><ref id="CIT0079"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>GT</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>K-K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Artemisinin-daumone hybrid inhibits cancer cell-mediated osteolysis by targeting cancer cells and osteoclasts</article-title>. <source>Cell Physiol Biochem</source>
<volume>49</volume>:<fpage>1460</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">30205376</pub-id></mixed-citation></ref><ref id="CIT0080"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macedo</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ladeira</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Pinho</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Bone metastases: an overview</article-title>. <source>Oncol Rev</source>
<volume>11</volume>:<fpage>321</fpage>.<pub-id pub-id-type="pmid">28584570</pub-id></mixed-citation></ref><ref id="CIT0081"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Bettencourt</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Bone regeneration: biomaterials as local delivery systems with improved osteoinductive properties</article-title>. <source>Mater Sci Eng C Mater Biol Appl</source>
<volume>82</volume>:<fpage>363</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">29025670</pub-id></mixed-citation></ref><ref id="CIT0082"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#x000fc;ller</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Neufurth</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Amorphous, smart, and bioinspired polyphosphate nano/microparticles: a biomaterial for regeneration and repair of osteo-articular impairments in-situ</article-title>. <source>IJMS</source>
<volume>19</volume>:<fpage>427</fpage>.</mixed-citation></ref><ref id="CIT0083"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Benoit</surname><given-names>DSW.</given-names></name></person-group> (<year>2016</year>). <article-title>Local and targeted drug delivery for bone regeneration</article-title>. <source>Curr Opin Biotechnol</source>
<volume>40</volume>:<fpage>125</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">27064433</pub-id></mixed-citation></ref><ref id="CIT0084"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nooh</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Sato</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration</article-title>. <source>J Bone Oncol</source>
<volume>6</volume>:<fpage>8</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">28138422</pub-id></mixed-citation></ref><ref id="CIT0085"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norouzi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nazari</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>DW.</given-names></name></person-group> (<year>2016</year>). <article-title>Injectable hydrogel-based drug delivery systems for local cancer therapy</article-title>. <source>Drug Discov Today</source>
<volume>21</volume>:<fpage>1835</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">27423369</pub-id></mixed-citation></ref><ref id="CIT0086"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#x02019;Carrigan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>MHF</given-names></name>, <name name-style="western"><surname>Willson</surname><given-names>ML</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Bisphosphonates and other bone agents for breast cancer</article-title>. <source>Coch Datab System Rev</source>
<volume>2</volume>:<fpage>CD003474</fpage>.</mixed-citation></ref><ref id="CIT0087"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oledzka</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Pachowska</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Or&#x00142;owska</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Pamidronate-conjugated biodegradable branched copolyester carriers: synthesis and characterization</article-title>. <source>Molecules</source>
<volume>22</volume>:<fpage>1063</fpage>.</mixed-citation></ref><ref id="CIT0088"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olthof</surname><given-names>MGL</given-names></name>, <name name-style="western"><surname>Kempen</surname><given-names>DHR</given-names></name>, <name name-style="western"><surname>Herrick</surname><given-names>JL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Effect of different sustained bone morphogenetic protein-2 release kinetics on bone formation in poly(propylene fumarate) scaffolds</article-title>. <source>J Biomed Mater Res B Appl Biomater</source>
<volume>106</volume>:<fpage>477</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">28186684</pub-id></mixed-citation></ref><ref id="CIT0089"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palam&#x000e0;</surname><given-names>IE</given-names></name>, <name name-style="western"><surname>Arcadio</surname><given-names>V</given-names></name>, <name name-style="western"><surname>D&#x02019;Amone</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Therapeutic PCL scaffold for reparation of resected osteosarcoma defect</article-title>. <source>Sci Rep</source>
<volume>7</volume>:<fpage>12672</fpage>.<pub-id pub-id-type="pmid">28978922</pub-id></mixed-citation></ref><ref id="CIT0090"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez-Herrero</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Fernandez-Medarde</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy</article-title>. <source>Eur J Pharm Biopharm</source>
<volume>93</volume>:<fpage>52</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="pmid">25813885</pub-id></mixed-citation></ref><ref id="CIT0091"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pore</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Hahm</surname><given-names>E-R</given-names></name>, <name name-style="western"><surname>Latoche</surname><given-names>JD</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Prevention of breast cancer-induced osteolytic bone resorption by benzyl isothiocyanate</article-title>. <source>Carcinogenesis</source>
<volume>39</volume>:<fpage>134</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">29040431</pub-id></mixed-citation></ref><ref id="CIT0092"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Posadowska</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Parizek</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Filova</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2015</year>). <article-title>Injectable nanoparticle-loaded hydrogel system for local delivery of sodium alendronate</article-title>. <source>Int J Pharm</source>
<volume>485</volume>:<fpage>31</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">25747455</pub-id></mixed-citation></ref><ref id="CIT0093"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Probert</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Dottorini</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Speakman</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis</article-title>. <source>Oncogene</source>
<volume>38</volume>:<fpage>1751</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">30353168</pub-id></mixed-citation></ref><ref id="CIT0094"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiao</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Targeting osteocytes to attenuate early breast cancer bone metastasis by theranostic upconversion nanoparticles with responsive plumbagin release</article-title>. <source>ACS Nano</source>
<volume>11</volume>:<fpage>7259</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">28692257</pub-id></mixed-citation></ref><ref id="CIT0095"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahmanian</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Naghib</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Seyfoori</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Tricalcium phosphate nanostructures loaded with bisphosphonate as potential anticancer agents</article-title>. <source>J Ceramic Sci Technol</source>
<volume>8</volume>:<fpage>505</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="CIT0096"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahmanian</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Seyfoori</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dehghan</surname><given-names>MM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Multifunctional gelatin-tricalcium phosphate porous nanocomposite scaffolds for tissue engineering and local drug delivery: in&#x000a0;vitro and in&#x000a0;vivo studies</article-title>. <source>J Taiwan Inst Chem Eng</source>
<volume>101</volume>:<fpage>214</fpage>&#x02013;<lpage>20</lpage>.</mixed-citation></ref><ref id="CIT0097"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Reinhold</surname><given-names>WC.</given-names></name></person-group> (<year>2015</year>). <article-title>Bisphosphonates as new anticancer agents?</article-title>
<source>Bull Cancer</source>
<volume>102</volume>:<fpage>297</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">26042254</pub-id></mixed-citation></ref><ref id="CIT0098"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Esser</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Fox</surname><given-names>GC</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Bone-induced expression of integrin &#x003b2;3 enables targeted nanotherapy of breast cancer metastases</article-title>. <source>Cancer Res</source>
<volume>77</volume>:<fpage>6299</fpage>&#x02013;<lpage>312</lpage>.<pub-id pub-id-type="pmid">28855208</pub-id></mixed-citation></ref><ref id="CIT0099"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudnick-Glick</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Corem-Salkmon</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Grinberg</surname><given-names>I</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model</article-title>. <source>J Nanobiotechnol</source>
<volume>14</volume>:<fpage>80</fpage>.</mixed-citation></ref><ref id="CIT0100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryu</surname><given-names>T-K</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>R-H</given-names></name>, <name name-style="western"><surname>Jeong</surname><given-names>K-Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Bone-targeted delivery of nanodiamond-based drug carriers conjugated with alendronate for potential osteoporosis treatment</article-title>. <source>J Control Release</source>
<volume>232</volume>:<fpage>152</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">27094604</pub-id></mixed-citation></ref><ref id="CIT0101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santini</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Galluzzo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zoccoli</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2010</year>). <article-title>New molecular targets in bone metastases</article-title>. <source>Cancer Treat Rev</source>
<volume>36</volume>:<fpage>S6</fpage>&#x02013;<lpage>S10</lpage>.<pub-id pub-id-type="pmid">21129612</pub-id></mixed-citation></ref><ref id="CIT0102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santini</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Stumbo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Spoto</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2015</year>). <article-title>Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence</article-title>. <source>Breast Cancer Res</source>
<volume>17</volume>:<fpage>121</fpage>.<pub-id pub-id-type="pmid">26328589</pub-id></mixed-citation></ref><ref id="CIT0103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saracino</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Luciano</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Battafarano</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Nanoparticles-based treatment for bone metastasis</article-title>. <source>Curr Drug Targets</source>
<volume>17</volume>:<fpage>303</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">25915486</pub-id></mixed-citation></ref><ref id="CIT0104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saravanakumar</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>WJ.</given-names></name></person-group> (<year>2017</year>). <article-title>Reactive-oxygen-species-responsive drug delivery systems: promises and challenges</article-title>. <source>Adv Sci</source>
<volume>4</volume>:<fpage>1600124</fpage>.</mixed-citation></ref><ref id="CIT0105"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sarigol-Calamak</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hascicek</surname><given-names>C.</given-names></name></person-group> (<year>2018</year>). <chapter-title>Tissue scaffolds as a local drug delivery system for bone regeneration</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Chun</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Kwon</surname><given-names>IK</given-names></name>, <name name-style="western"><surname>Khang</surname><given-names>G</given-names></name>, eds.</person-group>
<source>Cutting-edge enabling technologies for regenerative medicine</source>. <publisher-loc>Singapore, Singapore</publisher-loc>: <publisher-name>Springer</publisher-name>, <fpage>475</fpage>&#x02013;<lpage>93</lpage>.</mixed-citation></ref><ref id="CIT0106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sethi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>XD</given-names></name>, <name name-style="western"><surname>Winter</surname><given-names>CG</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2011</year>). <article-title>Tumor-derived jagged1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells</article-title>. <source>Cancer Cell</source>
<volume>19</volume>:<fpage>192</fpage>&#x02013;<lpage>205</lpage>.<pub-id pub-id-type="pmid">21295524</pub-id></mixed-citation></ref><ref id="CIT0107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shupp</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Kolb</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Mukhopadhyay</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Cancer metastases to bone: concepts, mechanisms, and interactions with bone osteoblasts</article-title>. <source>Cancers</source>
<volume>10</volume>:<fpage>182</fpage>.</mixed-citation></ref><ref id="CIT0108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>CS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Current development of biodegradable polymeric materials for biomedical applications</article-title>. <source>Drug Des Devel Ther</source>
<volume>12</volume>:<fpage>3117</fpage>&#x02013;<lpage>45</lpage>.</mixed-citation></ref><ref id="CIT0109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stapleton</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sawamoto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Almeciga-Diaz</surname><given-names>CJ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Development of bone targeting drugs</article-title>. <source>IJMS</source>
<volume>18</volume>:<fpage>1345</fpage>.</mixed-citation></ref><ref id="CIT0110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stopeck</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Fizazi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Body</surname><given-names>JJ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer</article-title>. <source>Support Care Cancer</source>
<volume>24</volume>:<fpage>447</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">26335402</pub-id></mixed-citation></ref><ref id="CIT0111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stopeck</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Lipton</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Body</surname><given-names>J-J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2010</year>). <article-title>Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study</article-title>. <source>J Clin Oncol</source>
<volume>28</volume>:<fpage>5132</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">21060033</pub-id></mixed-citation></ref><ref id="CIT0112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strazic-Geljic</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Guberovic</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Didak</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases</article-title>. <source>Biochem Pharmacol</source>
<volume>116</volume>:<fpage>11</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">27378505</pub-id></mixed-citation></ref><ref id="CIT0113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suk</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>QG</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>PEGylation as a strategy for improving nanoparticle-based drug and gene delivery</article-title>. <source>Adv Drug Deliv Rev</source>
<volume>99</volume>:<fpage>28</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">26456916</pub-id></mixed-citation></ref><ref id="CIT0114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>YY</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>XY</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Mitochondria-targeted hydroxyapatite nanoparticles for selective growth inhibition of lung cancer in&#x000a0;vitro and in&#x000a0;vivo</article-title>. <source>ACS Appl Mater Interfaces</source>
<volume>8</volume>:<fpage>25680</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">27602785</pub-id></mixed-citation></ref><ref id="CIT0115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Ge</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Bone-targeted nanoplatform combining zoledronate and photothermal therapy to treat breast cancer bone metastasis</article-title>. <source>ACS Nano</source>
<volume>13</volume>:<fpage>7556</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">31259530</pub-id></mixed-citation></ref><ref id="CIT0116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Bone-targeted mesoporous silica nanocarrier anchored by zoledronate for cancer bone metastasis</article-title>. <source>Langmuir</source>
<volume>32</volume>:<fpage>9237</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">27531422</pub-id></mixed-citation></ref><ref id="CIT0117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Licorice isoliquiritigenin-encapsulated mesoporous silica nanoparticles for osteoclast inhibition and bone loss prevention</article-title>. <source>Theranostics</source>
<volume>9</volume>:<fpage>5183</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">31410209</pub-id></mixed-citation></ref><ref id="CIT0118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>L-L</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>SX-A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Ca<sup>2+</sup>, pH and thermo triple-responsive mechanized Zr-based MOFs for on-command drug release in bone diseases</article-title>. <source>J Mater Chem B</source>
<volume>4</volume>:<fpage>135</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">32262817</pub-id></mixed-citation></ref><ref id="CIT0119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Self-assembling bisphosphonates into nanofibers to enhance their inhibitory capacity on bone resorption</article-title>. <source>Nanoscale</source>
<volume>8</volume>:<fpage>10570</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">27153349</pub-id></mixed-citation></ref><ref id="CIT0120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thummuri</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jeengar</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Shrivastava</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2015</year>). <article-title>Thymoquinone prevents RANKL-induced osteoclastogenesis activation and osteolysis in an in&#x000a0;vivo model of inflammation by suppressing NF-KB and MAPK Signalling</article-title>. <source>Pharmacol Res</source>
<volume>99</volume>:<fpage>63</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">26022736</pub-id></mixed-citation></ref><ref id="CIT0121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turpin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Duterque-Coquillaud</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vieillard</surname><given-names>M-H.</given-names></name></person-group> (<year>2020</year>). <article-title>Bone metastasis: current state of play</article-title>. <source>Transl Oncol</source>
<volume>13</volume>:<fpage>308</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">31877463</pub-id></mixed-citation></ref><ref id="CIT0122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulbrich</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hola</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Subr</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies</article-title>. <source>Chem Rev</source>
<volume>116</volume>:<fpage>5338</fpage>&#x02013;<lpage>431</lpage>.<pub-id pub-id-type="pmid">27109701</pub-id></mixed-citation></ref><ref id="CIT0123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanderburgh</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>MK</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2020</year>). <article-title>Tuning ligand density to optimize pharmacokinetics of targeted nanoparticles for dual protection against tumor-induced bone destruction</article-title>. <source>Acs Nano</source>
<volume>14</volume>:<fpage>311</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">31894963</pub-id></mixed-citation></ref><ref id="CIT0124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanderburgh</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Kwakwa</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Werfel</surname><given-names>TA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease</article-title>. <source>J Controlled Release</source>
<volume>311-312</volume>:<fpage>257</fpage>&#x02013;<lpage>72</lpage>.</mixed-citation></ref><ref id="CIT0125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinay</surname><given-names>R</given-names></name>, <name name-style="western"><surname>KusumDevi</surname><given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>Potential of targeted drug delivery system for the treatment of bone metastasis</article-title>. <source>Drug Deliv</source>
<volume>23</volume>:<fpage>21</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">24839990</pub-id></mixed-citation></ref><ref id="CIT0126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>A targeted and pH-responsive bortezomib nanomedicine in the treatment of metastatic bone tumors</article-title>. <source>ACS Appl Mater Interfaces</source>
<volume>10</volume>:<fpage>41003</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">30403331</pub-id></mixed-citation></ref><ref id="CIT0127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>In vivo evaluation of reduction-responsive alendronate-hyaluronan-curcumin polymer-drug conjugates for targeted therapy of bone metastatic breast cancer</article-title>. <source>Mol Pharm</source>
<volume>15</volume>:<fpage>2764</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">29792799</pub-id></mixed-citation></ref><ref id="CIT0128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>He</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Multifunctional melanin-like nanoparticles for bone-targeted chemo-photothermal therapy of malignant bone tumors and osteolysis</article-title>. <source>Biomaterials</source>
<volume>183</volume>:<fpage>10</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30144589</pub-id></mixed-citation></ref><ref id="CIT0129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Mo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Raddeanin A suppresses breast cancer-associated osteolysis through inhibiting osteoclasts and breast cancer cells</article-title>. <source>Cell Death Dis</source>
<volume>9</volume>:<fpage>376</fpage>.<pub-id pub-id-type="pmid">29515110</pub-id></mixed-citation></ref><ref id="CIT0130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2015</year>). <article-title>Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-&#x003ba;B signaling pathways</article-title> . <source>Breast Cancer Res Treat</source>
<volume>149</volume>:<fpage>705</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">25667102</pub-id></mixed-citation></ref><ref id="CIT0131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>WY</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>CX</given-names></name>, <name name-style="western"><surname>Mao</surname><given-names>LK</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>The biological activities, chemical stability, metabolism and delivery systems of quercetin: a review</article-title>. <source>Trends Food Sci Technol</source>
<volume>56</volume>:<fpage>21</fpage>&#x02013;<lpage>38</lpage>.</mixed-citation></ref><ref id="CIT0132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Mei</surname><given-names>Z</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2020</year>). <article-title>3D printed biodegradable implants as an individualized drug delivery system for local chemotherapy of osteosarcoma</article-title>. <source>Mater Des</source>
<volume>186</volume>:<fpage>108336</fpage>.</mixed-citation></ref><ref id="CIT0133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2014</year>). <article-title>Redox-responsive polyanhydride micelles for cancer therapy</article-title>. <source>Biomaterials</source>
<volume>35</volume>:<fpage>3080</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">24388799</pub-id></mixed-citation></ref><ref id="CIT0134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B-K</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>X-F</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J-H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Gold-nanorods-siRNA nanoplex for improved photothermal therapy by gene silencing</article-title>. <source>Biomaterials</source>
<volume>78</volume>:<fpage>27</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">26646625</pub-id></mixed-citation></ref><ref id="CIT0135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Overexpression of suppressor of cytokine signaling 3 in dorsal root ganglion attenuates cancer-induced pain in rats</article-title>. <source>Mol Pain</source>
<volume>13</volume>:<fpage>1744806916688901</fpage>.<pub-id pub-id-type="pmid">28326931</pub-id></mixed-citation></ref><ref id="CIT0136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Local release of gemcitabine via in situ UV-crosslinked lipid-strengthened hydrogel for inhibiting osteosarcoma</article-title>. <source>Drug Deliv</source>
<volume>25</volume>:<fpage>1642</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">30799654</pub-id></mixed-citation></ref><ref id="CIT0137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>GY</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>YZ</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2004</year>). <article-title>Glutathione metabolism and its implications for health</article-title>. <source>J Nutr</source>
<volume>134</volume>:<fpage>489</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">14988435</pub-id></mixed-citation></ref><ref id="CIT0138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>XQ</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>FF</given-names></name>, <name name-style="western"><surname>Dang</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2020</year>). <article-title>RANKL/RANK system-based mechanism for breast cancer bone metastasis and related therapeutic strategies</article-title>. <source>Front Cell Dev Biol</source>
<volume>8</volume>:<fpage>76</fpage>.<pub-id pub-id-type="pmid">32117996</pub-id></mixed-citation></ref><ref id="CIT0139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>RX</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Pei</surname><given-names>XH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Effects of Brucine on the OPG/RANKL/RANK Signaling Pathway in MDA-MB-231 and MC3T3-E1 Cell Coculture System</article-title>. <source>Evidence-Based Complementary and Alternative Medicine</source>
<volume>2017</volume>:<fpage>1</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="CIT0140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Niu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2020</year>). <article-title>Engineering a biodegradable multifunctional antibacterial bioactive nanosystem for enhancing tumor photothermo-chemotherapy and bone regeneration</article-title>. <source>ACS Nano</source>
<volume>14</volume>:<fpage>442</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">31702885</pub-id></mixed-citation></ref><ref id="CIT0141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>A carboxyl-terminated dendrimer enables osteolytic lesion targeting and photothermal ablation of malignant bone tumors</article-title>. <source>ACS Appl Mater Interfaces</source>
<volume>11</volume>:<fpage>160</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">30525391</pub-id></mixed-citation></ref><ref id="CIT0142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>XW</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2020</year>). <article-title>Curcumin has immunomodulatory effects on RANKL-stimulated osteoclastogenesis in&#x000a0;vitro and titanium nanoparticle-induced bone loss in&#x000a0;vivo</article-title>. <source>J Cell Mol Med</source>
<volume>24</volume>:<fpage>1553</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">31845532</pub-id></mixed-citation></ref><ref id="CIT0143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>YX</given-names></name>, <name name-style="western"><surname>Hua</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>MK</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Fabrication and characterization of electrospinning/3D printing bone tissue engineering scaffold</article-title>. <source>RSC Adv</source>
<volume>6</volume>:<fpage>110557</fpage>&#x02013;<lpage>65</lpage>.</mixed-citation></ref><ref id="CIT0144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Lian</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Phosphatidyl inositol 3-kinase (PI3K)-mTOR inhibitor PKI-402 inhibits breast cancer induced osteolysis</article-title>. <source>Cancer Lett</source>
<volume>443</volume>:<fpage>135</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">30540926</pub-id></mixed-citation></ref><ref id="CIT0145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hoque</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Varghese</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Biomaterial-assisted local and systemic delivery of bioactive agents for bone repair</article-title>. <source>Acta Biomater</source>
<volume>93</volume>:<fpage>152</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">30711659</pub-id></mixed-citation></ref><ref id="CIT0146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>LB</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>ZB</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>W</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Inhibitory effect of quercetin on titanium particle induced endoplasmic reticulum stress related apoptosis and in&#x000a0;vivo osteolysis</article-title>. <source>Bioscience Reports</source>
<volume>37</volume>:<fpage>BSR20170961</fpage>.<pub-id pub-id-type="pmid">28760844</pub-id></mixed-citation></ref><ref id="CIT0147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Application of hydroxyapatite nanoparticles in tumor-associated bone segmental defect</article-title>. <source>Sci Adv</source>
<volume>5</volume>:<fpage>eaax6946</fpage>.<pub-id pub-id-type="pmid">31414050</pub-id></mixed-citation></ref><ref id="CIT0148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>YY</given-names></name>, <name name-style="western"><surname>Zou</surname><given-names>BH</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>YH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Sinomenine inhibits osteolysis in breast cancer by reducing IL-8/CXCR1 and c-Fos/NFATc1 signaling</article-title>. <source>Pharmacol Res</source>
<volume>142</volume>:<fpage>140</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">30797069</pub-id></mixed-citation></ref><ref id="CIT0149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>P-P</given-names></name>, <name name-style="western"><surname>Ge</surname><given-names>Y-W</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X-L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2020</year>). <article-title>Ordered arrangement of hydrated GdPO4 nanorods in magnetic chitosan matrix promotes tumor photothermal therapy and bone regeneration against breast cancer bone metastases</article-title>. <source>Chem Eng J</source>
<volume>381</volume>:<fpage>122694</fpage>.</mixed-citation></ref><ref id="CIT0150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y-P</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>W-L</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>D-Z</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Redox and pH dual sensitive bone targeting nanoparticles to treat breast cancer bone metastases and inhibit bone resorption</article-title>. <source>Nanoscale</source>
<volume>9</volume>:<fpage>6264</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">28470315</pub-id></mixed-citation></ref><ref id="CIT0151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>YQ</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>DQ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>The role of spinal GABAB receptors in cancer-induced bone pain in rats</article-title>. <source>J Pain</source>
<volume>18</volume>:<fpage>933</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">28323246</pub-id></mixed-citation></ref><ref id="CIT0152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Nonviral cancer gene therapy: delivery cascade and vector nanoproperty integration</article-title>. <source>Adv Drug Deliv Rev</source>
<volume>115</volume>:<fpage>115</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">28778715</pub-id></mixed-citation></ref><ref id="CIT0153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Huo</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy</article-title>. <source>Nanoscale</source>
<volume>10</volume>:<fpage>18387</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">30256367</pub-id></mixed-citation></ref></ref-list></back></article>